Document and Entity Information	9 Months Ended
Document and Entity Information	Dec. 31, 2013	Jan. 31, 2014
Entity Information [Line Items]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Dec. 31, 2013
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		51,800,179

Consolidated Statements of Income and Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenues
Net sales	$ 145,054	$ 159,492	$ 454,159	$ 466,735
Other revenues	1,158	740	3,466	2,349
Total revenues	146,212	160,232	457,625	469,084
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	64,403	75,235	197,614	209,938
Gross profit	81,809	84,997	260,011	259,146
Operating Expenses
Advertising and promotion	25,570	23,538	70,754	67,371
General and administrative	12,137	11,378	35,390	40,114
Depreciation and amortization	3,644	3,359	10,206	9,950
Total operating expenses	41,351	38,275	116,350	117,435
Operating income	40,458	46,722	143,661	141,711
Other (income) expense
Interest income	(16)	(4)	(44)	(9)
Interest expense	21,276	26,665	53,648	66,178
Loss on extinguishment of debt	15,012	0	15,012	0
Total other expense	36,272	26,661	68,616	66,169
Income before income taxes	4,186	20,061	75,045	75,542
Provision for income taxes	1,056	7,804	18,431	29,386
Net income	3,130	12,257	56,614	46,156
Earnings per share:
Basic (in USD per share)	$ 0.06	$ 0.24	$ 1.10	$ 0.91
Diluted (in USD per share)	$ 0.06	$ 0.24	$ 1.08	$ 0.90
Weighted average shares outstanding:
Basic (in shares)	51,806	50,686	51,498	50,465
Diluted (in shares)	52,445	51,523	52,236	51,285
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,694)	(1)	(1,571)	23
Total other comprehensive (loss) income	(2,694)	(1)	(1,571)	23
Comprehensive income	$ 436	$ 12,256	$ 55,043	$ 46,179

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2013
Current assets
Cash and cash equivalents	$ 94,353	$ 15,670
Accounts receivable, net	66,188	73,053
Inventories	64,798	60,201
Deferred income tax assets	6,836	6,349
Prepaid expenses and other current assets	12,326	8,900
Total current assets	244,501	164,173
Property and equipment, net	10,528	9,896
Goodwill	189,955	167,546
Intangible assets, net	1,395,755	1,373,240
Other long-term assets	24,107	24,944
Total Assets	1,864,846	1,739,799
Current liabilities
Current portion of long-term debt	48,290	0
Accounts payable	51,547	51,376
Accrued interest payable	10,781	13,894
Other accrued liabilities	23,445	31,398
Total current liabilities	134,063	96,668
Long-term debt
Principal amount	985,000	978,000
Less unamortized discount	(3,489)	(7,100)
Long-term debt, net of unamortized discount	981,511	970,900
Deferred income tax liabilities	205,036	194,288
Other long-term liabilities	302	0
Total Liabilities	1,320,912	1,261,856
Commitments and Contingencies — Note 17
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Preferred share rights	283	283
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 51,961 shares at December 31, 2013 and 51,311 shares at March 31, 2013	520	513
Additional paid-in capital	412,910	401,691
Treasury stock, at cost - 194 shares at December 31, 2013 and 181 shares March 31, 2013	(965)	(687)
Accumulated other comprehensive loss, net of tax	(1,675)	(104)
Retained earnings	132,861	76,247
Total Stockholders' Equity	543,934	477,943
Total Liabilities and Stockholders' Equity	$ 1,864,846	$ 1,739,799

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	51,961,000	51,311,000
Treasury stock, shares	194,000	181,000

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Activities
Net income	$ 56,614	$ 46,156
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	10,209	9,950
Deferred income taxes	10,261	15,979
Amortization of deferred financing costs	6,023	8,220
Stock-based compensation costs	3,763	2,965
Loss on extinguishment of debt	15,012	0
Premium payment on 2010 Senior Notes	(12,768)	0
Amortization of debt discount	3,115	3,892
Lease termination costs	0	975
(Gain) loss on sale or disposal of property and equipment	(3)	51
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	8,495	(13,518)
Inventories	(2,262)	(3,351)
Prepaid expenses and other current assets	(2,783)	5,801
Accounts payable	(1,285)	14,125
Accrued liabilities	(13,531)	9,631
Net cash provided by operating activities	80,860	100,876
Investing Activities
Purchases of property and equipment	(2,658)	(8,922)
Proceeds from the sale of property and equipment	3	15
Proceeds from the sale of the Phazyme brand	0	21,700
Acquisition of brands from GSK purchase price adjustments	0	(226)
Acquisition of Care Pharmaceuticals, less cash acquired	(55,215)	0
Net cash (used in) provided by investing activities	(57,870)	12,567
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	400,000	0
Repayment of 2010 Senior Notes	(201,710)	0
Repayments of long-term debt	(147,500)	(167,500)
Repayments under revolving credit agreement	(45,500)	(8,000)
Borrowings under revolving credit agreement	50,000	48,000
Payment of deferred financing costs	(6,933)	0
Proceeds from exercise of stock options	5,738	5,460
Excess tax benefits from share-based awards	1,725	0
Fair value of shares surrendered as payment of tax withholding	(278)	0
Net cash provided by (used in) financing activities	55,542	(122,040)
Effects of exchange rate changes on cash and cash equivalents	151	13
Increase (decrease) in cash and cash equivalents	78,683	(8,584)
Cash and cash equivalents - beginning of period	15,670	19,015
Cash and cash equivalents - end of period	94,353	10,431
Interest paid	47,586	54,149
Income taxes paid	$ 9,761	$ 7,183

Business and Basis of Presentation

9 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, club, convenience, and dollar stores in the United States and Canada and in certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to the Consolidated Financial Statements.

Basis of Presentation

The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements. In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31^st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2014”) mean our fiscal year ending or ended on March 31^st of that year. Operating results for the three and nine months ended December 31, 2013 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2014. This financial information should be read in conjunction with our Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at December 31, 2013 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year. If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.

Deferred Financing Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. These costs are capitalized as deferred financing costs and amortized using the effective interest method, over the term of the related debt.

Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were $7.6 million and $23.3 million for the three and nine months ended December 31, 2013, respectively, and $7.6 million and $23.1 million for the three and nine months ended December 31, 2012, respectively.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period an employee or director is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In July 2013, the FASB issued Accounting Standards Updated ("ASU") 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which requires that an unrecognized tax benefit, or portion of an unrecognized tax benefit, be presented as a reduction of a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward. If an applicable deferred tax asset is not available to use or the tax law of the applicable jurisdiction does not require the entity to use and the company does not intend to use the applicable deferred tax asset, the unrecognized tax benefit should be presented as a liability in the financial statements and should not be combined with an unrelated deferred tax asset. ASU 2013-11 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date; however retrospective application is permitted. The adoption of ASU 2013-11 is not expected to have a material impact on our Consolidated Financial Statements.

In March 2013, the FASB issued ASU 2013-05, Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, relating to the release of cumulative translation adjustments into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2013-05 is not expected to have a material impact on our Consolidated Financial Statements.

In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires that for those items that are reclassified out of accumulated other comprehensive income and into net income in their entirety, the effect of the reclassification on each affected net income line item be disclosed. For accumulated other comprehensive income reclassification items that are not reclassified in their entirety into net income, a cross reference must be made to other required disclosures. The guidance is effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 did not have a material impact on our Consolidated Financial Statements. See Note 13 Accumulated Other Comprehensive Loss for required disclosure.

In December 2011, the FASB issued ASU 2011-11, Disclosures about Offsetting Assets and Liabilities, regarding disclosures about offsetting assets and liabilities. The new disclosure requirements mandate that entities disclose both gross and net information about instruments and transactions eligible for offset in the statement of financial position, as well as instruments and transactions subject to an agreement similar to a master netting arrangement. In addition, the standard requires disclosure of collateral received and posted in connection with master netting agreements or similar arrangements. An entity will be required to disclose the following information for assets and liabilities within the scope of the new standard: (i) the gross amounts of those recognized assets and those recognized liabilities; (ii) the amounts offset to determine the net amounts presented in the statement of financial position; (iii) the net amounts presented in the statement of financial position; (iv) the amounts subject to an enforceable master netting arrangement or similar agreement not otherwise included in (ii); and (v) the net amount after deducting the amounts in (iv) from the amounts in (iii). The standard affects all entities with balances presented on a net basis in the financial statements, derivative assets and derivative liabilities, repurchase agreements, and financial assets and financial liabilities executed under a master netting or similar arrangement. This guidance is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. This new guidance did not have a material impact on our Consolidated Financial Statements.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

Acquisitions

9 Months Ended

Dec. 31, 2013

Business Combinations [Abstract]

Acquisitions

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharmaceuticals Pty Ltd. (“Care Pharma”), which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also carries a line of brands for children including Little Allergies, Little Eyes, and Little Coughs. The brands acquired are complementary to our existing OTC Healthcare portfolio.

This acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared a preliminary analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,103

Accounts payable	1,537
Accrued expenses	2,505
Other long term liabilities	300
Total liabilities assumed	4,342

Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at December 31, 2013 was 14.1 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro-forma effect of this acquisition on revenues and earnings was not material.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Divestitures

9 Months Ended

Dec. 31, 2013

Discontinued Operations and Disposal Groups [Abstract]

Divestitures

Sale of the Phazyme Brand

On October 31, 2012, we divested the Phazyme gas treatment brand, which was a non-core OTC brand that we acquired from GlaxoSmithKline ("GSK") in January 2012. We received $21.7 million from the divestiture on October 31, 2012 and the remaining $0.6 million on January 4, 2013. The proceeds were used to repay debt. No significant gain or loss was recorded as a result of the sale.

Concurrent with the completion of the sale of the Phazyme brand, we entered into a Transitional Services Agreement with the buyer (the “Phazyme TSA”), whereby we agreed to provide the buyer with various services, including marketing, operations, finance and other services, from the date of the acquisition primarily through January 31, 2013, with an option for additional support for the Canadian portion of that business through October 31, 2013, at the buyer's discretion. All Phazyme United States TSA services ended, as agreed, on January 31, 2013. The buyer elected to extend the Canadian portion of the TSA services on a month to month basis and terminated the support on October 31, 2013.

The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:



(In thousands)	October 31, 2012
Components of assets sold:
Inventory	$	220
Prepaid expenses	100
Trade names	15,604
Goodwill	6,382

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

+ Details

Accounts Receivable

9 Months Ended

Dec. 31, 2013

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:



(In thousands)	December 31, 2013			March 31, 2013
Components of Accounts Receivable
Trade accounts receivable	$	74,025		$	79,746
Other receivables	1,709			615
	75,734			80,361
Less allowances for discounts, returns and uncollectible accounts	(9,546		)	(7,308		)
Accounts receivable, net	$	66,188		$	73,053

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References+ Details

Inventories

9 Months Ended

Dec. 31, 2013

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



(In thousands)	December 31, 2013		March 31, 2013
Components of Inventories
Packaging and raw materials	$	1,455	$	1,875
Finished goods	63,343		58,326
Inventories	$	64,798	$	60,201

Inventories are carried at the lower of cost or market, which includes a reduction in inventory values of $2.6 million and $1.3 million at December 31, 2013 and March 31, 2013, respectively, related to obsolete and slow-moving inventory.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Property and Equipment

9 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following:



(In thousands)	December 31, 2013			March 31, 2013
Components of Property and Equipment
Machinery	$	1,870		$	1,580
Computer equipment and software	8,886			6,559
Furniture and fixtures	1,826			1,510
Leasehold improvements	4,732			4,713
	17,314			14,362
Accumulated depreciation	(6,786		)	(4,466		)
Property and equipment, net	$	10,528		$	9,896

We recorded depreciation expense of $1.1 million and $0.4 million for the three months ended December 31, 2013 and December 31, 2012, respectively, and $2.2 million and $1.0 million for the nine months ended December 31, 2013 and December 31, 2012, respectively. Additionally, during the nine months ended December 31, 2012, we wrote-off leasehold improvements with a remaining net book value of less than $0.1 million due to the relocation of our corporate offices.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Goodwill

9 Months Ended

Dec. 31, 2013

Goodwill [Abstract]

Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:



(In thousands)	OTC Healthcare			Household Cleaning		Consolidated

Balance — March 31, 2013	$	160,157		$	7,389	$	167,546
Additions	23,122			—		23,122
Effects of foreign currency exchange rates	(713		)	—		(713		)
Balance — December 31, 2013	$	182,566		$	7,389	$	189,955

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the preliminary fair value of the net assets acquired.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.

On an annual basis, during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of the values assigned to goodwill and tests for impairment.

At March 31, 2013, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2013. As of December 31, 2013, there have been no triggering events that would indicate potential impairment.

The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2013, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

Intangible Assets

9 Months Ended

Dec. 31, 2013

Intangible Assets [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:



(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement			Totals
Gross Carrying Amounts
Balance — March 31, 2013	$	1,243,718		$	203,066		$	158		$	1,446,942
Additions	29,845			1,657			—			31,502
Reductions	—			—			(158		)	(158		)
Effects of foreign currency exchange rates	(919		)	(51		)	—			(970		)
Balance — December 31, 2013	$	1,272,644		$	204,672		$	—		$	1,477,316

Accumulated Amortization
Balance — March 31, 2013	$	—		$	73,544		$	158		$	73,702
Additions	—			8,019			—			8,019
Reductions	—			—			(158		)	(158		)
Effects of foreign currency exchange rates	—			(2		)	—			(2		)
Balance — December 31, 2013	$	—		$	81,561		$	—		$	81,561

Intangible assets, net - December 31, 2013	$	1,272,644		$	123,111		$	—		$	1,395,755

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we allocated $31.5 million to intangible assets based on our preliminary analysis.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and must also be tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis during the fourth fiscal quarter of each year, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.

In a manner similar to goodwill, we completed our annual test for impairment of our indefinite-lived intangible assets during the three months ended March 31, 2013. We did not record an impairment charge, as facts and circumstances indicated that the fair values of the intangible assets for our brands exceeded their carrying values. Additionally, for the indefinite-lived intangible assets, an evaluation of the facts and circumstances as of December 31, 2013 continues to support an indefinite useful life for these assets. Therefore, no impairment charge was recorded for the nine months ended December 31, 2013.

The weighted average remaining life for finite-lived intangible assets at December 31, 2013 was approximately 13.8 years and the amortization expense for the three and nine months ended December 31, 2013 was $2.6 million and $8.0 million, respectively. At December 31, 2013, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:



(In thousands)
Year Ending March 31,	Amount
2014 (Remaining three months ending March 31, 2014)	$	2,235
2015	8,949
2016	8,949
2017	8,949
2018	8,949
Thereafter	85,080
	$	123,111

Other Accrued Liabilities

9 Months Ended

Dec. 31, 2013

Payables and Accruals [Abstract]

Other Accrued Liabilities

Other accrued liabilities consist of the following:



(In thousands)	December 31, 2013		March 31, 2013

Accrued marketing costs	$	11,845	$	17,187
Accrued compensation costs	5,378		8,847
Accrued broker commissions	941		1,028
Income taxes payable	—		493
Accrued professional fees	3,794		1,846
Deferred rent	1,254		1,268
Accrued lease termination costs	180		729
Other accrued liabilities	53		—
	$	23,445	$	31,398

Long-Term Debt

9 Months Ended

Dec. 31, 2013

Debt Disclosure [Abstract]

Long-Term Debt

2010 Senior Notes:

On March 24, 2010, Prestige Brands, Inc. (the "Borrower") issued $150.0 million of senior unsecured notes, with an interest rate of 8.25% and a maturity date of April 1, 2018 (the "2010 Senior Notes"). On November 1, 2010, the Borrower issued an additional $100.0 million of the 2010 Senior Notes. The Borrower may earlier redeem some or all of the 2010 Senior Notes at redemption prices set forth in the indenture governing the 2010 Senior Notes. The 2010 Senior Notes issued in March and November 2010 were issued at an aggregate face value of $150.0 million and $100.0 million, respectively, with a discount to the initial purchasers of $2.2 million and a premium of $0.3 million, respectively, and net proceeds to the Company of $147.8 million and $100.3 million, respectively, yielding an 8.5% effective interest rate for the 2010 Senior Notes on a combined basis. The 2010 Senior Notes are unconditionally guaranteed by Prestige Brands Holdings, Inc. and its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. On December 17, 2013, we offered to redeem the 2010 Senior Notes at a premium of 6.33%, of which $201.7 million were redeemed on such date. The remaining $48.3 million were redeemed on January 16, 2014, which is included in our current liabilities as of December 31, 2013. As a result, during the quarter ended December 31, 2013, we recorded a $15.0 million loss on the early extinguishment of debt relating to the $201.7 million 2010 Senior Notes redeemed and will record an additional loss of approximately $3.3 million on the remaining $48.3 million tendered on January 16, 2014. This loss consists of premium payments of $12.8 million, write-off of deferred financing costs of $1.7 million, and write-off of debt discount of $0.5 million.

2012 Senior Notes:

On January 31, 2012, the Borrower issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In September 2012, we utilized a portion of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $25.0 million to $75.0 million, and in June 2013, we further increased the amount of our borrowing capacity under the 2012 ABL Revolver by $20.0 million to $95.0 million and also reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Company of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Amendment") to the 2012 Term Loan. The Amendment provides for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans. The interest rate on the Term B-1 Loans is based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate plus a margin. The new Term B-1 Loans will mature on the same date as the Term B Loans' original maturity date. In addition, the Amendment provides the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with the Amendment, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

During the three months ended December 31, 2012, as a result of our significant debt repayments, we accelerated a portion of the deferred financing costs and original issue discount related to our 2012 Term Loan. As a result, during the three months ended December 31, 2012, we recorded a $7.7 million pre-tax charge to interest expense related to this non-cash acceleration. Of the $7.7 million, $3.0 million relates to the prior three quarters. Had the timing of the accelerated amortization been properly recorded, pre-tax earnings for the three and nine months ended December 31, 2012 would have been higher by $3.0 million ($1.9 million after tax, or $0.03 per diluted share) and $1.1 million ($0.7 million after tax or $0.01 per diluted share), respectively; pre-tax earnings in the first and second quarters of 2013 would have been lower by $1.2 million ($0.7 million after tax or $0.02 per diluted share) and $0.7 million ($0.5 million after tax, or $0.01 per diluted share), respectively; and pre-tax earnings in the fourth quarter of 2012 and the year ended March 31, 2012 would have been lower by $1.1 million ($0.7 million after tax, or $0.01 per diluted share). We do not believe the amounts were material to the consolidated financial statements for any prior period and the cumulative amount is not material to the estimated results of operations for the year ended March 31, 2013. Furthermore, the adjustments had no impact to our cash flows from operations or total cash flows.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, provided that LIBOR shall not be lower than 1.00%. For the nine months ended December 31, 2013, the average interest rate on the 2012 Term Loan was 4.0%.

Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.

Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments in an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the nine months ended December 31, 2013, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.0%.

We used the net proceeds from the 2012 Senior Notes offering, together with borrowings under the 2012 Term Loan, to finance the acquisition of the 17 North American OTC healthcare brands from GSK (the "GSK Brands"), to repay the balance of our then outstanding credit facility, to pay fees and expenses incurred in connection with these transactions and for general corporate purposes.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $6.7 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

Guarantees and Subordination:

The 2010 Senior Notes, which have been redeemed, are secured on a pari passu basis with the 2012 Term Loan and are guaranteed on a senior secured basis. The 2012 Senior Notes and the 2013 Senior Notes are senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis. The 2010 Senior Notes are effectively junior in right of payment to all existing and future secured obligations of the Company, equal in right of payment with all existing and future senior unsecured indebtedness of the Company, and senior in right of payment to all future subordinated debt of the Company. The 2012 Senior Notes and the 2013 Senior Notes are effectively subordinated to secured obligations of the Company, including the 2012 Term Loan and the 2012 ABL Revolver and the 2010 Senior Notes, equal in right of payment to all existing and future unsecured obligations of the Company, and senior in right of payment to all existing and future subordinated obligations of the Company.

At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest, if any, on the 2013 Senior Notes plus an applicable "make-whole premium". On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof plus accrued and unpaid interest to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met.

The indentures governing the 2010 Senior Notes, the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At December 31, 2013, we were in compliance with the covenants under our long-term indebtedness.

At December 31, 2013, we had an aggregate of $24.1 million of unamortized debt issuance costs and $3.5 million of unamortized debt discount. The total of which is comprised of $0.5 million related to the 2010 Senior Notes, $10.4 million related to the 2012 Senior Notes, $6.6 million related to the 2013 Senior Notes, $8.7 million related to the 2012 Term Loan, and $1.4 million related to the 2012 ABL Revolver.

During the nine months ended December 31, 2013, we borrowed a net amount of $4.5 million against the 2012 ABL Revolver.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	December 31, 2013			March 31, 2013
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year, commencing June 15, 2014. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	—
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term Loan bearing interest at the Company's option at either a base rate plus applicable margin with a floor of 2.00% or LIBOR with a floor of 1.00%, due on January 31, 2019.	297,500			445,000
2012 ABL Revolver bearing interest at the Company's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	37,500			33,000
2010 Senior Notes bearing interest at 8.25%, with interest payable on April 1 and October 1 of each year. The 2010 Senior Notes mature on April 1, 2018.	48,290			250,000
	1,033,290			978,000
Current portion of long-term debt	48,290			—
	985,000			978,000
Less: unamortized discount	(3,489		)	(7,100		)
Long-term debt, net of unamortized discount	$	981,511		$	970,900

As of December 31, 2013, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes, the 2012 Senior Notes, and the 2010 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2014 (remaining three months ending March 31, 2014)	$	48,290
2015	—
2016	—
2017	37,500
2018	—
Thereafter	947,500
	$	1,033,290

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2012 Term Loan, the 2013 Senior Notes, the 2012 Senior Notes, the 2010 Senior Notes and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At December 31, 2013 and March 31, 2013, we did not have any assets or liabilities measured in Level 1 or 3. During any of the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3. At December 31, 2013 the carrying value and market value of our 2013 Senior Notes was $400.0 million and $403.0 million, respectively. At December 31, 2013 and March 31, 2013, the carrying value of our 2012 Senior Notes was $250.0 million. The market value of our 2012 Senior Notes was $279.1 million and $281.9 million at December 31, 2013 and March 31, 2013, respectively. At December 31, 2013 and March 31, 2013, the carrying value of the 2012 Term Loan was $297.5 million and $445.0 million, respectively. The market value of the 2012 Term Loan was $299.0 million and $451.1 million at December 31, 2013 and March 31, 2013, respectively. At December 31, 2013 and March 31, 2013, the carrying value of our 2010 Senior Notes was $48.3 million and $250.0 million, respectively. The market value of our 2010 Senior Notes was $51.1 million and $271.9 million at December 31, 2013 and March 31, 2013, respectively. At December 31, 2013, the carrying value and market value of the 2012 ABL Revolver was $37.5 million. At March 31, 2013, the carrying value and market value of the 2012 ABL Revolver was $33.0 million.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Dec. 31, 2013
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through December 31, 2013. Pursuant to the provisions of various employee restricted stock awards, we repurchased 2,549 shares and 13,275 shares of restricted common stock from our employees during the three and nine months ended December 31, 2013, respectively. During the three and nine months ended December 31, 2012, we did not repurchase any shares of restricted common stock from our employees pursuant to the provisions of the various employee restricted stock awards. The repurchases during the nine months ended December 31, 2013 were at an average price of $27.81. All of the repurchased shares have been recorded as treasury stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Accumulated Other Comprehensive Loss

9 Months Ended

Dec. 31, 2013

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Loss

The table below presents accumulated other comprehensive loss (“AOCI”), which is comprised of various items that affect equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. As discussed in Note 1 above, ASU 2013-02 did not have a significant impact on our financial statements.

AOCI consisted of the following at December 31, 2013 and March 31, 2013:



	December 31,			March 31,
(In thousands)	2013			2013
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(1,675	)	$	(104	)
Total accumulated other comprehensive loss, net of tax	$	(1,675	)	$	(104	)

Earnings Per Share

9 Months Ended

Dec. 31, 2013

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2013		2012		2013		2012
Numerator
Net income	$	3,130	$	12,257	$	56,614	$	46,156

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	51,806		50,686		51,498		50,465
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	639		837		738		820
Denominator for diluted earnings per share	52,445		51,523		52,236		51,285

Earnings per Common Share:
Basic net earnings per share	$	0.06	$	0.24	$	1.10	$	0.91

Diluted net earnings per share	$	0.06	$	0.24	$	1.08	$	0.90

For the three months ended December 31, 2013 and 2012, there were 0.2 million and less than 0.1 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2013 and 2012, there were 0.2 million and less than 0.1 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Share-Based Compensation

9 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During the three months and nine months ended December 31, 2013, pre-tax share-based compensation costs charged against income were $1.3 million and $3.8 million, respectively, and the related income tax benefit recognized was $0.4 million and $1.1 million, respectively. During the three and nine months ended December 31, 2012, pre-tax share-based compensation costs charged against income were $1.0 million and $3.0 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.9 million, respectively.

Restricted Shares and Restricted Stock Units

Restricted shares and restricted stock units granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share and restricted stock unit awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

On May 14, 2013, the Compensation Committee of our Board of Directors granted 113,637 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 55,637 restricted stock units vest in their entirety on the three-year anniversary of the date of grant, and 58,000 restricted stock units vest 33.3% per year over three years. On November 5, 2013, the Compensation Committee of our Board of Directors granted 6,000 restricted stock units to certain employees under the Plan, which will vest 33.3% per year over three years. On July 29, 2013, the Compensation Committee of the Board of Directors granted 7,004 restricted stock units to the independent members of the Board of Directors under the Plan.

The fair value of the restricted stock units is determined using the closing price of our common stock on the day of grant. The weighted-average grant-date fair value of restricted stock units granted during the nine months ended December 31, 2013 and 2012 was $30.19 and $13.59, respectively.

A summary of the Company's restricted shares and restricted stock units granted under the Plan is presented below:



Restricted Shares and Restricted Stock Units	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Nine months ended December 31, 2012:
Outstanding at March 31, 2012	363.4		$	9.92
Granted	128.9		13.59
Vested and issued	(27.0	)	7.16
Forfeited	(12.3	)	10.69
Outstanding at December 31, 2012	453.0		11.11
Vested at December 31, 2012	70.4		8.52

Nine months ended December 31, 2013:
Outstanding at March 31, 2013	421.3		$	11.01
Granted	126.6		30.19
Vested and issued	(59.7	)	8.42
Forfeited	(5.6	)	15.11
Outstanding at December 31, 2013	482.6		16.32
Vested at December 31, 2013	83.1		9.63

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option. On May 14, 2013, the Compensation Committee of our Board of Directors granted stock options to acquire 227,672 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $29.94 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

The weighted-average grant-date fair value of the options granted during the nine months ended December 31, 2013 and 2012 was $13.94 and $6.03, respectively.



	Nine Months Ended December 31,
	2013			2012
Expected volatility	48.0		%	44.0		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.5
Risk-free rate	1.3		%	1.2		%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Nine months ended December 31, 2012:
Outstanding at March 31, 2012	1,745.4		$	8.44
Granted	444.9		13.36
Exercised	(708.5	)	7.71
Forfeited or expired	(17.4	)	11.21
Outstanding at December 31, 2012	1,464.4		10.26		7.7	$	11,330
Exercisable at December 31, 2012	332.4		9.99		6.8	2,248

Nine months ended December 31, 2013:
Outstanding at March 31, 2013	1,386.4		$	10.43
Granted	227.7		29.94
Exercised	(589.9	)	9.73
Forfeited or expired	(14.2	)	14.56
Outstanding at December 31, 2013	1,010.0		15.18		7.6	$	20,828
Exercisable at December 31, 2013	172.1		11.34		6.8	4,210

The aggregate intrinsic value of options exercised in the nine months ended December 31, 2013 was $13.7 million. The aggregate intrinsic value for options granted during the nine months ended December 31, 2013 was $1.3 million.

At December 31, 2013, there were $5.0 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 0.9 years. The total fair value of options and restricted shares vested during the nine months ended December 31, 2013 and 2012 was $3.2 million and $2.1 million, respectively. For the nine months ended December 31, 2013 and 2012, cash received from the exercise of stock options was $5.7 million and $5.4 million, respectively, and we realized $1.7 million and $9.3 million, respectively, in tax benefits for the tax deductions resulting from these option exercises. At December 31, 2013, there were 1.6 million shares available for issuance under the Plan.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Income Taxes	9 Months Ended
Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rate used in the calculation of income taxes was 25.2% and 38.9% for the three months ended December 31, 2013 and December 31, 2012, respectively. The effective tax rate used in the calculation of income taxes was 24.6% and 38.9% for the nine months ended December 31, 2013 and December 31, 2012, respectively. The decrease in the effective tax rate for the three months ended December 31, 2013 was primarily due to the impact of lower state income tax rates on the lower profitability of the Company due primarily to the loss on debt extinguishment. The decrease in the effective tax rate for the nine months ended December 31, 2013 was primarily due to a one-time benefit of $0.4 million and $8.9 million, respectively, to adjust our current and deferred tax balances for lower state income taxes. This benefit was primarily related to a recent law change in the state where we have our major distribution center to tax earnings attributed to in-state revenues only. At December 31, 2013, a wholly-owned subsidiary had a net operating loss carryforward of approximately $1.0 million, which may be used to offset future taxable income of the consolidated group and which begins to expire in 2020. The net operating loss carryforward is subject to an annual limitation as to usage of approximately $0.2 million pursuant to Internal Revenue Code Section 382. We experienced a net increase of $0.2 million in our uncertain tax liability during the nine months ended December 31, 2013. Therefore, the balance in our uncertain tax liability was $1.2 million and $1.0 million at December 31, 2013 and March 31, 2013, respectively. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Commitments and Contingencies

9 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment in New York and Wyoming, which expire at various dates through 2018. Due to the acquisition of the GSK Brands, we required additional office space and entered into a 5.5 year lease for a new office facility in New York, which began in the third quarter of fiscal 2013. In May 2012, we also entered into a three year lease for an office in Rogers, Arkansas. These amounts have been included in the schedule below.

The following summarizes future minimum lease payments for our operating leases as of December 31, 2013:



(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2014 (Remaining three months ending March 31, 2014)	$	459	$	35	$	494
2015	1,049		136		1,185
2016	994		135		1,129
2017	1,023		68		1,091
2018	1,044		—		1,044
Thereafter	—		—		—
	$	4,569	$	374	$	4,943

Rent expense for each of the three months ended December 31, 2013 and 2012 was $0.4 million and $0.3 million, respectively, while rent expense for each of the nine months ended December 31, 2013 and 2012 was $1.2 million and $0.9 million, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,	Amount
2014 (Remaining three months ending March 31, 2014)	$	281
2015	1,105
2016	1,074
2017	1,044
2018	1,013
Thereafter	1,542
	$	6,059

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Concentrations of Risk	9 Months Ended
Concentrations of Risk	Dec. 31, 2013
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and dollar and club stores. During the three and nine months ended December 31, 2013, approximately 41.1% and 41.7%, respectively, of our total revenues were derived from our five top selling brands. During the three and nine months ended December 31, 2012, approximately 40.3% and 40.7%, respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 20.4% and 19.7%, respectively, of our gross revenues for the three and nine months ended December 31, 2013, and approximately 21.5% and 21.3%, respectively, of our gross revenues for the three and nine months ended December 31, 2012. At December 31, 2013, approximately 20.2% of accounts receivable were owed by the same customer. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At December 31, 2013, we had relationships with 58 third-party manufacturers pertaining to our domestic operations. Of those, we had long-term contracts with 21 manufacturers that produced items that accounted for approximately 86.3% of gross sales for the nine months ended December 31, 2013. At December 31, 2012, we had relationships with 62 third-party manufacturers. Of those, we had long-term contracts with 24 manufacturers that produced items that accounted for approximately 77.1% of gross sales for the nine months ended December 31, 2012. The fact that we do not have long-term contracts with certain manufacturers means they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details

Business Segments

9 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current operating and reportable segments consist of (i) OTC Healthcare and (ii) Household Cleaning. There were no inter-segment sales or transfers during any of the periods presented. We evaluate the performance of our operating segments and allocate resources to them based primarily on contribution margin.

The tables below summarize information about our operating and reportable segments.



	Three Months Ended December 31, 2013						Nine Months Ended December 31, 2013
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated		OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	125,448	$	19,606	$	145,054	$	390,670	$	63,489	$	454,159
Other revenues	150		1,008		1,158		462		3,004		3,466
Total revenues	125,598		20,614		146,212		391,132		66,493		457,625
Cost of sales	49,042		15,361		64,403		149,378		48,236		197,614
Gross profit	76,556		5,253		81,809		241,754		18,257		260,011
Advertising and promotion	24,830		740		25,570		68,375		2,379		70,754
Contribution margin	$	51,726	$	4,513	56,239		$	173,379	$	15,878	189,257
Other operating expenses					15,781						45,596
Operating income					40,458						143,661
Other expense					36,272						68,616
Income before income taxes					4,186						75,045
Provision for income taxes					1,056						18,431
Net income					$	3,130					$	56,614



	Three Months Ended December 31, 2012						Nine Months Ended December 31, 2012
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated		OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	138,858	$	20,634	$	159,492	$	402,633	$	64,102	$	466,735
Other revenues	175		565		740		520		1,829		2,349
Total revenues	139,033		21,199		160,232		403,153		65,931		469,084
Cost of sales	59,381		15,854		75,235		160,249		49,689		209,938
Gross profit	79,652		5,345		84,997		242,904		16,242		259,146
Advertising and promotion	22,410		1,128		23,538		62,309		5,062		67,371
Contribution margin	$	57,242	$	4,217	61,459		$	180,595	$	11,180	191,775
Other operating expenses					14,737						50,064
Operating income					46,722						141,711
Other expense					26,661						66,169
Income before income taxes					20,061						75,542
Provision for income taxes					7,804						29,386
Net income					$	12,257					$	46,156

The table below summarizes information about our revenues from similar product groups.



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2013		2012		2013		2012
Analgesics	$	25,903	$	27,946	$	84,634	$	81,727
Cough & Cold	34,330		37,424		89,548		94,197
Gastrointestinal	20,190		24,977		64,841		74,510
Eye & Ear Care	19,400		19,702		63,519		63,109
Dermatologicals	9,797		11,496		40,223		41,578
Oral Care	11,408		12,953		35,845		36,032
Other OTC	4,570		4,535		12,522		12,000
Total OTC Healthcare Segment	125,598		139,033		391,132		403,153
Household Cleaning Segment	20,614		21,199		66,493		65,931
Consolidated Total Revenues	$	146,212	$	160,232	$	457,625	$	469,084

During the three and nine months ended December 31, 2013, approximately 85.7% and 87.2%, respectively, of our sales were made to customers in the United States, while during the three and nine months ended December 31, 2012, approximately 89.1% and 89.9% , respectively, of our sales were made to customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three and nine months ended December 31, 2013, sales to Canada accounted for approximately 8.3% and 7.8%, respectively, of our total revenues, while during the three and nine months ended December 31, 2012 approximately 8.1% and 7.5%, respectively, of our total revenue was attributable to sales to Canada.

At December 31, 2013, substantially all of our long-term assets were located in the United States and have been allocated to the operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	182,566	$	7,389	$	189,955

Intangible assets
Indefinite-lived	1,152,824		119,820		1,272,644
Finite-lived	96,508		26,603		123,111
	1,249,332		146,423		1,395,755
	$	1,431,898	$	153,812	$	1,585,710

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Condensed Consolidating Financial Statements

9 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Financial Statements

As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, have fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes, including, without limitation, the obligation to pay principal and interest with respect to the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes. Although holders of the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes, 2012 Senior Notes or the 2010 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes, 2012 Senior Notes or the 2010 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes, 2012 Senior Notes and the 2010 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of December 31, 2013 and March 31, 2013, Condensed Consolidating Income and Comprehensive Income Statements for the three and nine months ended December 31, 2013 and 2012, and Condensed Consolidating Statements of Cash Flows for the nine months ended December 31, 2013 and 2012. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the issuer,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.

In the third quarter of fiscal 2014, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the second quarter of fiscal 2014. This resulted in an understatement of equity in earnings of subsidiaries for Prestige Brands, Inc. (the "Issuer") of $48.1 million, an overstatement of $0.6 million for Prestige Brands Holdings, Inc. (the "Parent")and a net understatement of equity in earnings of subsidiaries for the eliminations of $47.5 million for each of the three and six month periods ended September 30, 2013. These items also resulted in corresponding adjustments to the Investments in subsidiaries on the balance sheet as of September 30, 2013 and adjustments to net income (loss) and equity in income of subsidiaries in the statement of cash flows, although net cash provided by operating activities for the six months ended September 30, 2013 remained unchanged. Revisions were also made to increase the cumulative translation adjustment of the Issuer and subsidiary guarantors by approximately $1 million each, with corresponding adjustments to the Investment in subsidiaries and stockholders' equity balances.

The Company assessed the materiality of these items on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the revisions were not material to the consolidated financial statements. The Company will disclose the impact of the revisions on previously reported amounts and accordingly revised the Condensed Consolidating Financial Statements for comparative periods in its future filings. There were no changes to any of the Company's Consolidated Financial Statements.

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,689		$	113,685		$	7,502		$	(1,822	)	$	145,054
Other revenues	—			75			1,160			10			(87		)	1,158
Total revenues	—			25,764			114,845			7,512			(1,909		)	146,212

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,361			53,750			2,325			(1,033		)	64,403
Gross profit	—			16,403			61,095			5,187			(876		)	81,809

Operating Expenses
Advertising and promotion	—			2,066			21,359			2,145			—			25,570
General and administrative	165			2,132			8,967			873			—			12,137
Depreciation and amortization	983			149			2,440			72			—			3,644
Total operating expenses	1,148			4,347			32,766			3,090			—			41,351
Operating income (loss)	(1,148		)	12,056			28,329			2,097			(876		)	40,458

Other (income) expense
Interest (income)	(12,305		)	(14,437		)	(731		)	(6		)	27,463			(16		)
Interest expense	8,671			21,276			18,061			731			(27,463		)	21,276
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(1,148		)	(6,845		)	(999		)	—			8,992			—
Total other (income) expense	(4,782		)	15,006			16,331			725			8,992			36,272
Income before income taxes	3,634			(2,950		)	11,998			1,372			(9,868		)	4,186
Provision (benefit) for income taxes	504			(2,541		)	2,720			373			—			1,056
Net income (loss)	$	3,130		$	(409	)	$	9,278		$	999		$	(9,868	)	$	3,130

Comprehensive income, net of tax:
Currency translation adjustments	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Total other comprehensive income (loss)	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Comprehensive income (loss)	$	436		$	(3,103	)	$	6,584		$	(1,695	)	$	(1,786	)	$	436

Condensed Consolidating Statements of Income and Comprehensive Income

Nine Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	75,339		$	364,468		$	16,174		$	(1,822	)	$	454,159
Other revenues	—			210			3,454			1,112			(1,310		)	3,466
Total revenues	—			75,549			367,922			17,286			(3,132		)	457,625

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,157			165,252			6,461			(2,256		)	197,614
Gross profit	—			47,392			202,670			10,825			(876		)	260,011

Operating Expenses
Advertising and promotion	—			9,254			57,751			3,749			—			70,754
General and administrative	2,555			5,256			25,782			1,797			—			35,390
Depreciation and amortization	2,017			434			7,625			130			—			10,206
Total operating expenses	4,572			14,944			91,158			5,676			—			116,350
Operating income (loss)	(4,572		)	32,448			111,512			5,149			(876		)	143,661

Other (income) expense
Interest (income)	(37,296		)	(42,765		)	(1,441		)	(30		)	81,488			(44		)
Interest expense	25,965			53,648			54,082			1,441			(81,488		)	53,648
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Total other (income) expense	(62,678		)	(16,102		)	49,774			1,411			96,211			68,616
Income before income taxes	58,106			48,550			61,738			3,738			(97,087		)	75,045
Provision (benefit) for income taxes	1,492			1,609			14,459			871			—			18,431
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614

Comprehensive income, net of tax:
Currency translation adjustments	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Total other comprehensive income (loss)	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Comprehensive income (loss)	$	55,043		$	45,370		$	45,708		$	1,296		$	(92,374	)	$	55,043

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,345		$	132,881		$	1,266		$	—		$	159,492
Other revenues	—			79			724			276			(339		)	740
Total revenues	—			25,424			133,605			1,542			(339		)	160,232

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,877			65,172			525			(339		)	75,235
Gross profit	—			15,547			68,433			1,017			—			84,997

Operating Expenses
Advertising and promotion	—			3,032			19,997			509			—			23,538
General and administrative	952			1,585			8,734			107			—			11,378
Depreciation and amortization	549			140			2,658			12			—			3,359
Total operating expenses	1,501			4,757			31,389			628			—			38,275
Operating income (loss)	(1,501		)	10,790			37,044			389			—			46,722

Other (income) expense
Interest (income)	33			(41,552		)	162			(62		)	41,415			(4		)
Interest expense	8,735			35,394			23,951			—			(41,415		)	26,665
Equity in (income) loss of subsidiaries	(18,531		)	(8,407		)	(393		)	—			27,331			—
Total other (income) expense	(9,763		)	(14,565		)	23,720			(62		)	27,331			26,661
Income before income taxes	8,262			25,355			13,324			451			(27,331		)	20,061
Provision (benefit) for income taxes	(3,995		)	6,593			5,030			176			—			7,804
Net income	$	12,257		$	18,762		$	8,294		$	275		$	(27,331	)	$	12,257

Comprehensive income, net of tax:
Currency translation adjustments	(1		)	(1		)	(1		)	(1		)	3			(1		)
Total other comprehensive income	(1		)	(1		)	(1		)	(1		)	3			(1		)
Comprehensive income	$	12,256		$	18,761		$	8,293		$	274		$	(27,328	)	$	12,256

Condensed Consolidating Statements of Income and Comprehensive Income

Nine Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	75,294		$	387,815		$	3,626		$	—		$	466,735
Other revenues	—			220			2,310			1,270			(1,451		)	2,349
Total revenues	—			75,514			390,125			4,896			(1,451		)	469,084

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,493			181,382			1,514			(1,451		)	209,938
Gross profit	—			47,021			208,743			3,382			—			259,146

Operating Expenses
Advertising and promotion	—			8,917			57,326			1,128			—			67,371
General and administrative	3,676			5,020			30,802			616			—			40,114
Depreciation and amortization	818			420			8,667			45			—			9,950
Total operating expenses	4,494			14,357			96,795			1,789			—			117,435
Operating income (loss)	(4,494		)	32,664			111,948			1,593			—			141,711

Other (income) expense
Interest (income)	(24,337		)	(63,573		)	162			(163		)	87,902			(9		)
Interest expense	26,147			92,320			35,613			—			(87,902		)	66,178
Equity in (income) loss of subsidiaries	(50,008		)	(49,280		)	(1,306		)	—			100,594			—
Total other (income) expense	(48,198		)	(20,533		)	34,469			(163		)	100,594			66,169
Income before income taxes	43,704			53,197			77,479			1,756			(100,594		)	75,542
Provision (benefit) for income taxes	(2,452		)	1,524			29,631			683			—			29,386
Net income	$	46,156		$	51,673		$	47,848		$	1,073		$	(100,594	)	$	46,156

Comprehensive income, net of tax:
Currency translation adjustments	23			23			23			23			(69		)	23
Total other comprehensive income	23			23			23			23			(69		)	23
Comprehensive income	$	46,179		$	51,696		$	47,871		$	1,096		$	(100,663	)	$	46,179

Condensed Consolidating Balance Sheet

December 31, 2013




(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353
Accounts receivable, net	127			14,349			47,631			4,081			—			66,188
Inventories	—			14,660			46,020			4,994			(876		)	64,798
Deferred income tax assets	251			917			5,668			—			—			6,836
Prepaid expenses and other current assets	8,148			66			3,313			799			—			12,326
Total current assets	99,173			29,992			102,632			13,580			(876		)	244,501

Property and equipment, net	9,905			125			229			269			—			10,528
Goodwill	—			66,007			101,540			22,408			—			189,955
Intangible assets, net	—			192,995			1,172,004			30,756			—			1,395,755
Other long-term assets	—			24,107			—			—			—			24,107
Intercompany receivable	596,369			1,919,068			588,046			9,501			(3,112,984		)	—
Investment in subsidiary	1,536,312			735,694			8,259			—			(2,280,265		)	—
Total Assets	$	2,241,759		$	2,967,988		$	1,972,710		$	76,514		$	(5,394,125	)	$	1,864,846

Liabilities and Stockholders' Equity
Current liabilities
Current portion of long-term debt	$	—		$	48,290		$	—		$	—		$	—		$	48,290
Accounts payable	3,063			11,641			34,320			2,523			—			51,547
Accrued interest payable	—			10,781			—			—			—			10,781
Other accrued liabilities	6,144			3,299			10,249			3,753			—			23,445
Total current liabilities	9,207			74,011			44,569			6,276			—			134,063

Long-term debt
Principal amount	—			985,000			—			—			—			985,000
Less unamortized discount	—			(3,489		)	—			—			—			(3,489		)
Long-term debt, net of unamortized discount	—			981,511			—			—			—			981,511

Deferred income tax liabilities	—			55,316			149,652			68			—			205,036
Long term liabilities	—			—			—			302			—			302
Intercompany payable	1,688,618			394,359			992,745			37,262			(3,112,984		)	—
Total Liabilities	1,697,825			1,505,197			1,186,966			43,908			(3,112,984		)	1,320,912

Stockholders' Equity
Preferred share rights	283			—			—			—			—			283
Common stock	520			—			—			—			—			520
Additional paid-in capital	412,910			1,337,706			658,799			23,815			(2,020,320		)	412,910
Treasury stock, at cost - 194 shares	(965		)	—			—			—			—			(965		)
Accumulated other comprehensive income, net of tax	(1,675		)	(1,675		)	(1,675		)	(1,675		)	5,025			(1,675		)
Retained earnings (accumulated deficit)	132,861			126,760			128,620			10,466			(265,846		)	132,861
Total Stockholders' Equity	543,934			1,462,791			785,744			32,606			(2,281,141		)	543,934
Total Liabilities and Stockholders' Equity	$	2,241,759		$	2,967,988		$	1,972,710		$	76,514		$	(5,394,125	)	$	1,864,846

Condensed Consolidating Balance Sheet

March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	14,720		$	—		$	—	$	950		$	—		$	15,670
Accounts receivable, net	21			13,875			58,345		812			—			73,053
Inventories	—			11,164			48,474		563			—			60,201
Deferred income tax assets	218			855			5,276		—			—			6,349
Prepaid expenses and other current assets	4,942			93			3,609		256			—			8,900
Total current assets	19,901			25,987			115,704		2,581			—			164,173

Property and equipment, net	9,609			34			253		—			—			9,896
Goodwill	—			66,007			101,539		—			—			167,546
Intangible assets, net	—			193,396			1,179,524		320			—			1,373,240
Other long-term assets	—			24,944			—		—			—			24,944
Intercompany receivable	653,049			1,911,573			415,587		7,316			(2,987,525		)	—
Investment in subsidiary	1,429,775			638,611			7,067		—			(2,075,453		)	—
Total Assets	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,601		$	10,600		$	37,695	$	480		$	—		$	51,376
Accrued interest payable	—			13,894			—		—			—			13,894
Other accrued liabilities	12,694			1,684			16,107		913			—			31,398
Total current liabilities	15,295			26,178			53,802		1,393			—			96,668

Long-term debt
Principal amount	—			978,000			—		—			—			978,000
Less unamortized discount	—			(7,100		)	—		—			—			(7,100		)
Long-term debt, net of unamortized discount	—			970,900			—		—			—			970,900

Deferred income tax liabilities	—			55,291			138,924		73			—			194,288
Intercompany payable	1,619,096			447,419			920,865		145			(2,987,525		)	—
Total Liabilities	1,634,391			1,499,788			1,113,591		1,611			(2,987,525		)	1,261,856

Stockholders' Equity
Preferred share rights	283			—			—		—			—			283
Common stock	513			—			—		—			—			513
Additional paid-in capital	401,691			1,280,945			624,742		1,111			(1,906,798		)	401,691
Treasury stock, at cost - 181 shares	(687		)	—			—		—			—			(687		)
Accumulated other comprehensive loss, net of tax	(104		)	—			—		(104		)	104			(104		)
Retained earnings (accumulated deficit)	76,247			79,819			81,341		7,599			(168,759		)	76,247
Total Stockholders' Equity	477,943			1,360,764			706,083		8,606			(2,075,453		)	477,943
Total Liabilities and Stockholders' Equity	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,017			434			7,624			134			—			10,209
Deferred income taxes	(33		)	(37		)	10,336			(5		)	—			10,261
Amortization of deferred financing costs	—			6,023			—			—			—			6,023
Stock-based compensation costs	3,763			—			—			—			—			3,763
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Premium payment on 2010 Senior Notes Tendered	—			(12,768		)	—			—			—			(12,768		)
Amortization of debt discount	—			3,115			—			—			—			3,115
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(106		)	(474		)	10,714			(1,639		)	—			8,495
Inventories	—			(3,496		)	2,454			(2,096		)	876			(2,262		)
Prepaid expenses and other current assets	(3,206		)	27			296			100			—			(2,783		)
Accounts payable	462			1,041			(3,375		)	587			—			(1,285		)
Accrued liabilities	(6,550		)	(1,498		)	(5,858		)	375			—			(13,531		)
Net cash provided by operating activities	1,614			12,323			66,600			323			—			80,860

Investing Activities
Purchases of property and equipment	(2,555		)	—			—			(103		)	—			(2,658		)
Proceeds from the sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash provided by (used in) investing activities	(2,555		)	(55,215		)	3			(103		)	—			(57,870		)

Financing Activities
Proceeds from the issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Payment of 2010 Senior Notes	—			(201,710		)	—			—			—			(201,710		)
Repayments of long-term debt	—			(147,500		)	—			—			—			(147,500		)
Repayments under revolving credit agreement	—			(45,500		)	—			—			—			(45,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(6,933		)	—			—			—			(6,933		)
Proceeds from exercise of stock options	5,738			—			—			—			—			5,738
Excess tax benefits from share-based awards	1,725			—			—			—			—			1,725
Shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	69,683			(5,465		)	(66,603		)	2,385			—			—
Net cash provided by (used in) financing activities	76,868			42,892			(66,603		)	2,385			—			55,542

Effect of exchange rate changes on cash and cash equivalents	—			—			—			151			—			151
Increase in cash and cash equivalents	75,927			—			—			2,756			—			78,683
Cash - beginning of period	14,720			—			—			950			—			15,670
Cash - end of period	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	46,156		$	51,673		$	47,848		$	1,073		$	(100,594	)	$	46,156
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	818			420			8,667			45			—			9,950
Deferred income taxes	143			44			15,796			(4		)	—			15,979
Amortization of deferred financing costs	—			8,220			—			—			—			8,220
Stock-based compensation costs	2,965			—			—			—			—			2,965
Lease termination costs	975			—			—			—			—			975
Amortization of debt discount	—			3,892			—			—			—			3,892
Loss on disposal of equipment	30			—			21			—			—			51
Equity in income of subsidiaries	(50,008		)	(49,280		)	(1,306		)	—			100,594			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(115		)	285			(13,474		)	(214		)	—			(13,518		)
Inventories	—			(1,242		)	(2,104		)	(5		)	—			(3,351		)
Prepaid expenses and other current assets	6,446			(369		)	(627		)	351			—			5,801
Accounts payable	(3,347		)	2,488			14,095			889			—			14,125
Accrued liabilities	(1,071		)	529			9,830			343			—			9,631
Net cash provided by (used in) operating activities	2,992			16,660			78,746			2,478			—			100,876

Investing Activities
Purchases of property and equipment	(8,922		)	—			—			—			—			(8,922		)
Proceeds from sale of property and equipment	—			—			15			—			—			15
Proceeds from the sale of the Phazyme brand	—			—			21,700			—			—			21,700
Acquisition of GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash (used in) provided by investing activities	(9,148		)	—			21,715			—			—			12,567

Financing Activities
Repayment of long-term debt	—			(167,500		)	—			—			—			(167,500		)
Repayments under revolving credit agreement	—			(8,000		)	—			—			—			(8,000		)
Borrowings under revolving credit agreement	—			48,000			—			—			—			48,000
Proceeds from exercise of stock options	5,460			—			—			—			—			5,460
Intercompany activity, net	(8,647		)	110,840			(100,461		)	(1,732		)	—			—
Net cash used in financing activities	(3,187		)	(16,660		)	(100,461		)	(1,732		)	—			(122,040		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			13			—			13
(Decrease) increase in cash and cash equivalents	(9,343		)	—			—			759			—			(8,584		)
Cash - beginning of period	18,221			—			—			794			—			19,015
Cash - end of period	$	8,878		$	—		$	—		$	1,553		$	—		$	10,431

Subsequent Events (Notes)	9 Months Ended
Subsequent Events (Notes)	Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Redemption of the 2010 Senior Notes: On December 17, 2013, we offered to redeem the 2010 Senior Notes at a premium of 6.33%, of which $201.7 million were redeemed on such date. The remaining $48.3 million were redeemed on January 16, 2014. As a result, during the quarter ended December 31, 2013, we recorded a $15.0 million loss on the early extinguishment of debt relating to the $201.7 million 2010 Senior Notes redeemed and will record an additional loss of approximately $3.3 million on the remaining $48.3 million tendered on January 16, 2014. Product Supply Disruption: One of the Company’s suppliers, which packages products accounting for approximately 8% of the Company’s sales, temporarily stopped production in mid-January and has not indicated when production will resume. We are in the process of qualifying alternative sources of supply and, until production resumes, will be allocating safety stock inventories. Until the supplier resumes production or alternative sources of supply are qualified, the Company may be unable to supply these products to its customers. We do not expect this supply interruption will have a material adverse effect in the fourth quarter of fiscal 2014, however, if unresolved, it could have a materially adverse effect on our business and results of operations in future periods.

Business and Basis of Presentation (Policies)

9 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Goodwill

Intangible Assets

Deferred Financing Costs

Revenue Recognition

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.

Advertising and Promotion Costs

Stock-based Compensation

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Recently Issued Accounting Standards

Business and Basis of Presentation (Tables)

9 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Acquisitions (Tables) (Care Pharma)

9 Months Ended

Dec. 31, 2013

Care Pharma

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,103

Accounts payable	1,537
Accrued expenses	2,505
Other long term liabilities	300
Total liabilities assumed	4,342

Net assets acquired	$	56,761

Divestitures (Tables)

9 Months Ended

Dec. 31, 2013

Discontinued Operations and Disposal Groups [Abstract]

Assets Sold and Associated Assets Held for Sale

The following table presents the assets sold at October 31, 2012 related to the Phazyme brand:



(In thousands)	October 31, 2012
Components of assets sold:
Inventory	$	220
Prepaid expenses	100
Trade names	15,604
Goodwill	6,382

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References+ Details

Accounts Receivable (Tables)

9 Months Ended

Dec. 31, 2013

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:



(In thousands)	December 31, 2013			March 31, 2013
Components of Accounts Receivable
Trade accounts receivable	$	74,025		$	79,746
Other receivables	1,709			615
	75,734			80,361
Less allowances for discounts, returns and uncollectible accounts	(9,546		)	(7,308		)
Accounts receivable, net	$	66,188		$	73,053

Goodwill (Tables)

9 Months Ended

Dec. 31, 2013

Goodwill [Abstract]

Reconciliation of the Activity Affecting Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows:



(In thousands)	OTC Healthcare			Household Cleaning		Consolidated

Balance — March 31, 2013	$	160,157		$	7,389	$	167,546
Additions	23,122			—		23,122
Effects of foreign currency exchange rates	(713		)	—		(713		)
Balance — December 31, 2013	$	182,566		$	7,389	$	189,955

Intangible Assets (Tables)

9 Months Ended

Dec. 31, 2013

Intangible Assets [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows:



(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks			Non Compete Agreement			Totals
Gross Carrying Amounts
Balance — March 31, 2013	$	1,243,718		$	203,066		$	158		$	1,446,942
Additions	29,845			1,657			—			31,502
Reductions	—			—			(158		)	(158		)
Effects of foreign currency exchange rates	(919		)	(51		)	—			(970		)
Balance — December 31, 2013	$	1,272,644		$	204,672		$	—		$	1,477,316

Accumulated Amortization
Balance — March 31, 2013	$	—		$	73,544		$	158		$	73,702
Additions	—			8,019			—			8,019
Reductions	—			—			(158		)	(158		)
Effects of foreign currency exchange rates	—			(2		)	—			(2		)
Balance — December 31, 2013	$	—		$	81,561		$	—		$	81,561

Intangible assets, net - December 31, 2013	$	1,272,644		$	123,111		$	—		$	1,395,755

Schedule of Expected Amortization Expense

At December 31, 2013, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:



(In thousands)
Year Ending March 31,	Amount
2014 (Remaining three months ending March 31, 2014)	$	2,235
2015	8,949
2016	8,949
2017	8,949
2018	8,949
Thereafter	85,080
	$	123,111

Long-Term Debt (Tables)

9 Months Ended

Dec. 31, 2013

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	December 31, 2013			March 31, 2013
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year, commencing June 15, 2014. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	—
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
2012 Term Loan bearing interest at the Company's option at either a base rate plus applicable margin with a floor of 2.00% or LIBOR with a floor of 1.00%, due on January 31, 2019.	297,500			445,000
2012 ABL Revolver bearing interest at the Company's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	37,500			33,000
2010 Senior Notes bearing interest at 8.25%, with interest payable on April 1 and October 1 of each year. The 2010 Senior Notes mature on April 1, 2018.	48,290			250,000
	1,033,290			978,000
Current portion of long-term debt	48,290			—
	985,000			978,000
Less: unamortized discount	(3,489		)	(7,100		)
Long-term debt, net of unamortized discount	$	981,511		$	970,900

Aggregate Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2014 (remaining three months ending March 31, 2014)	$	48,290
2015	—
2016	—
2017	37,500
2018	—
Thereafter	947,500
	$	1,033,290

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(e),(f))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Accumulated Other Comprehensive Loss (Tables)

9 Months Ended

Dec. 31, 2013

Accumulated Other Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Loss

AOCI consisted of the following at December 31, 2013 and March 31, 2013:



	December 31,			March 31,
(In thousands)	2013			2013
Components of Accumulated Other Comprehensive Loss
Cumulative translation adjustment	$	(1,675	)	$	(104	)
Total accumulated other comprehensive loss, net of tax	$	(1,675	)	$	(104	)

Earnings Per Share (Tables)

9 Months Ended

Dec. 31, 2013

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands, except per share data)	2013		2012		2013		2012
Numerator
Net income	$	3,130	$	12,257	$	56,614	$	46,156

Denominator
Denominator for basic earnings per share — weighted average shares outstanding	51,806		50,686		51,498		50,465
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	639		837		738		820
Denominator for diluted earnings per share	52,445		51,523		52,236		51,285

Earnings per Common Share:
Basic net earnings per share	$	0.06	$	0.24	$	1.10	$	0.91

Diluted net earnings per share	$	0.06	$	0.24	$	1.08	$	0.90

Share-Based Compensation (Tables)

9 Months Ended

Dec. 31, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company's restricted shares and restricted stock units granted under the Plan is presented below:



Restricted Shares and Restricted Stock Units	Shares (in thousands)		Weighted- Average Grant-Date Fair Value
Nine months ended December 31, 2012:
Outstanding at March 31, 2012	363.4		$	9.92
Granted	128.9		13.59
Vested and issued	(27.0	)	7.16
Forfeited	(12.3	)	10.69
Outstanding at December 31, 2012	453.0		11.11
Vested at December 31, 2012	70.4		8.52

Nine months ended December 31, 2013:
Outstanding at March 31, 2013	421.3		$	11.01
Granted	126.6		30.19
Vested and issued	(59.7	)	8.42
Forfeited	(5.6	)	15.11
Outstanding at December 31, 2013	482.6		16.32
Vested at December 31, 2013	83.1		9.63

Stock Options, Valuation Assumptions



	Nine Months Ended December 31,
	2013			2012
Expected volatility	48.0		%	44.0		%
Expected dividends	$	—		$	—
Expected term in years	6.0			6.5
Risk-free rate	1.3		%	1.2		%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Nine months ended December 31, 2012:
Outstanding at March 31, 2012	1,745.4		$	8.44
Granted	444.9		13.36
Exercised	(708.5	)	7.71
Forfeited or expired	(17.4	)	11.21
Outstanding at December 31, 2012	1,464.4		10.26		7.7	$	11,330
Exercisable at December 31, 2012	332.4		9.99		6.8	2,248

Nine months ended December 31, 2013:
Outstanding at March 31, 2013	1,386.4		$	10.43
Granted	227.7		29.94
Exercised	(589.9	)	9.73
Forfeited or expired	(14.2	)	14.56
Outstanding at December 31, 2013	1,010.0		15.18		7.6	$	20,828
Exercisable at December 31, 2013	172.1		11.34		6.8	4,210

Commitments and Contingencies (Tables)

9 Months Ended

Dec. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases as of December 31, 2013:



(In thousands)
Year Ending March 31,	Facilities		Equipment		Total
2014 (Remaining three months ending March 31, 2014)	$	459	$	35	$	494
2015	1,049		136		1,185
2016	994		135		1,129
2017	1,023		68		1,091
2018	1,044		—		1,044
Thereafter	—		—		—
	$	4,569	$	374	$	4,943

Unrecorded Unconditional Purchase Obligations Disclosure

Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,	Amount
2014 (Remaining three months ending March 31, 2014)	$	281
2015	1,105
2016	1,074
2017	1,044
2018	1,013
Thereafter	1,542
	$	6,059

Business Segments (Tables)

9 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our operating and reportable segments.



	Three Months Ended December 31, 2013						Nine Months Ended December 31, 2013
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated		OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	125,448	$	19,606	$	145,054	$	390,670	$	63,489	$	454,159
Other revenues	150		1,008		1,158		462		3,004		3,466
Total revenues	125,598		20,614		146,212		391,132		66,493		457,625
Cost of sales	49,042		15,361		64,403		149,378		48,236		197,614
Gross profit	76,556		5,253		81,809		241,754		18,257		260,011
Advertising and promotion	24,830		740		25,570		68,375		2,379		70,754
Contribution margin	$	51,726	$	4,513	56,239		$	173,379	$	15,878	189,257
Other operating expenses					15,781						45,596
Operating income					40,458						143,661
Other expense					36,272						68,616
Income before income taxes					4,186						75,045
Provision for income taxes					1,056						18,431
Net income					$	3,130					$	56,614



	Three Months Ended December 31, 2012						Nine Months Ended December 31, 2012
(In thousands)	OTC Healthcare		Household Cleaning		Consolidated		OTC Healthcare		Household Cleaning		Consolidated
Net sales	$	138,858	$	20,634	$	159,492	$	402,633	$	64,102	$	466,735
Other revenues	175		565		740		520		1,829		2,349
Total revenues	139,033		21,199		160,232		403,153		65,931		469,084
Cost of sales	59,381		15,854		75,235		160,249		49,689		209,938
Gross profit	79,652		5,345		84,997		242,904		16,242		259,146
Advertising and promotion	22,410		1,128		23,538		62,309		5,062		67,371
Contribution margin	$	57,242	$	4,217	61,459		$	180,595	$	11,180	191,775
Other operating expenses					14,737						50,064
Operating income					46,722						141,711
Other expense					26,661						66,169
Income before income taxes					20,061						75,542
Provision for income taxes					7,804						29,386
Net income					$	12,257					$	46,156

Information about our Revenues from Similar Product Groups

The table below summarizes information about our revenues from similar product groups.



	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2013		2012		2013		2012
Analgesics	$	25,903	$	27,946	$	84,634	$	81,727
Cough & Cold	34,330		37,424		89,548		94,197
Gastrointestinal	20,190		24,977		64,841		74,510
Eye & Ear Care	19,400		19,702		63,519		63,109
Dermatologicals	9,797		11,496		40,223		41,578
Oral Care	11,408		12,953		35,845		36,032
Other OTC	4,570		4,535		12,522		12,000
Total OTC Healthcare Segment	125,598		139,033		391,132		403,153
Household Cleaning Segment	20,614		21,199		66,493		65,931
Consolidated Total Revenues	$	146,212	$	160,232	$	457,625	$	469,084

Allocation of Long-Term Assets to Segments

At December 31, 2013, substantially all of our long-term assets were located in the United States and have been allocated to the operating segments as follows:



(In thousands)	OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	182,566	$	7,389	$	189,955

Intangible assets
Indefinite-lived	1,152,824		119,820		1,272,644
Finite-lived	96,508		26,603		123,111
	1,249,332		146,423		1,395,755
	$	1,431,898	$	153,812	$	1,585,710

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

Condensed Consolidating Financial Statements (Tables)

9 Months Ended

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,689		$	113,685		$	7,502		$	(1,822	)	$	145,054
Other revenues	—			75			1,160			10			(87		)	1,158
Total revenues	—			25,764			114,845			7,512			(1,909		)	146,212

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,361			53,750			2,325			(1,033		)	64,403
Gross profit	—			16,403			61,095			5,187			(876		)	81,809

Operating Expenses
Advertising and promotion	—			2,066			21,359			2,145			—			25,570
General and administrative	165			2,132			8,967			873			—			12,137
Depreciation and amortization	983			149			2,440			72			—			3,644
Total operating expenses	1,148			4,347			32,766			3,090			—			41,351
Operating income (loss)	(1,148		)	12,056			28,329			2,097			(876		)	40,458

Other (income) expense
Interest (income)	(12,305		)	(14,437		)	(731		)	(6		)	27,463			(16		)
Interest expense	8,671			21,276			18,061			731			(27,463		)	21,276
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(1,148		)	(6,845		)	(999		)	—			8,992			—
Total other (income) expense	(4,782		)	15,006			16,331			725			8,992			36,272
Income before income taxes	3,634			(2,950		)	11,998			1,372			(9,868		)	4,186
Provision (benefit) for income taxes	504			(2,541		)	2,720			373			—			1,056
Net income (loss)	$	3,130		$	(409	)	$	9,278		$	999		$	(9,868	)	$	3,130

Comprehensive income, net of tax:
Currency translation adjustments	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Total other comprehensive income (loss)	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Comprehensive income (loss)	$	436		$	(3,103	)	$	6,584		$	(1,695	)	$	(1,786	)	$	436

Condensed Consolidating Statements of Income and Comprehensive Income

Nine Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	75,339		$	364,468		$	16,174		$	(1,822	)	$	454,159
Other revenues	—			210			3,454			1,112			(1,310		)	3,466
Total revenues	—			75,549			367,922			17,286			(3,132		)	457,625

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,157			165,252			6,461			(2,256		)	197,614
Gross profit	—			47,392			202,670			10,825			(876		)	260,011

Operating Expenses
Advertising and promotion	—			9,254			57,751			3,749			—			70,754
General and administrative	2,555			5,256			25,782			1,797			—			35,390
Depreciation and amortization	2,017			434			7,625			130			—			10,206
Total operating expenses	4,572			14,944			91,158			5,676			—			116,350
Operating income (loss)	(4,572		)	32,448			111,512			5,149			(876		)	143,661

Other (income) expense
Interest (income)	(37,296		)	(42,765		)	(1,441		)	(30		)	81,488			(44		)
Interest expense	25,965			53,648			54,082			1,441			(81,488		)	53,648
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Total other (income) expense	(62,678		)	(16,102		)	49,774			1,411			96,211			68,616
Income before income taxes	58,106			48,550			61,738			3,738			(97,087		)	75,045
Provision (benefit) for income taxes	1,492			1,609			14,459			871			—			18,431
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614

Comprehensive income, net of tax:
Currency translation adjustments	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Total other comprehensive income (loss)	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Comprehensive income (loss)	$	55,043		$	45,370		$	45,708		$	1,296		$	(92,374	)	$	55,043

Condensed Consolidating Statements of Income and Comprehensive Income

Three Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	25,345		$	132,881		$	1,266		$	—		$	159,492
Other revenues	—			79			724			276			(339		)	740
Total revenues	—			25,424			133,605			1,542			(339		)	160,232

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,877			65,172			525			(339		)	75,235
Gross profit	—			15,547			68,433			1,017			—			84,997

Operating Expenses
Advertising and promotion	—			3,032			19,997			509			—			23,538
General and administrative	952			1,585			8,734			107			—			11,378
Depreciation and amortization	549			140			2,658			12			—			3,359
Total operating expenses	1,501			4,757			31,389			628			—			38,275
Operating income (loss)	(1,501		)	10,790			37,044			389			—			46,722

Other (income) expense
Interest (income)	33			(41,552		)	162			(62		)	41,415			(4		)
Interest expense	8,735			35,394			23,951			—			(41,415		)	26,665
Equity in (income) loss of subsidiaries	(18,531		)	(8,407		)	(393		)	—			27,331			—
Total other (income) expense	(9,763		)	(14,565		)	23,720			(62		)	27,331			26,661
Income before income taxes	8,262			25,355			13,324			451			(27,331		)	20,061
Provision (benefit) for income taxes	(3,995		)	6,593			5,030			176			—			7,804
Net income	$	12,257		$	18,762		$	8,294		$	275		$	(27,331	)	$	12,257

Comprehensive income, net of tax:
Currency translation adjustments	(1		)	(1		)	(1		)	(1		)	3			(1		)
Total other comprehensive income	(1		)	(1		)	(1		)	(1		)	3			(1		)
Comprehensive income	$	12,256		$	18,761		$	8,293		$	274		$	(27,328	)	$	12,256

Condensed Consolidating Statements of Income and Comprehensive Income

Nine Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	75,294		$	387,815		$	3,626		$	—		$	466,735
Other revenues	—			220			2,310			1,270			(1,451		)	2,349
Total revenues	—			75,514			390,125			4,896			(1,451		)	469,084

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,493			181,382			1,514			(1,451		)	209,938
Gross profit	—			47,021			208,743			3,382			—			259,146

Operating Expenses
Advertising and promotion	—			8,917			57,326			1,128			—			67,371
General and administrative	3,676			5,020			30,802			616			—			40,114
Depreciation and amortization	818			420			8,667			45			—			9,950
Total operating expenses	4,494			14,357			96,795			1,789			—			117,435
Operating income (loss)	(4,494		)	32,664			111,948			1,593			—			141,711

Other (income) expense
Interest (income)	(24,337		)	(63,573		)	162			(163		)	87,902			(9		)
Interest expense	26,147			92,320			35,613			—			(87,902		)	66,178
Equity in (income) loss of subsidiaries	(50,008		)	(49,280		)	(1,306		)	—			100,594			—
Total other (income) expense	(48,198		)	(20,533		)	34,469			(163		)	100,594			66,169
Income before income taxes	43,704			53,197			77,479			1,756			(100,594		)	75,542
Provision (benefit) for income taxes	(2,452		)	1,524			29,631			683			—			29,386
Net income	$	46,156		$	51,673		$	47,848		$	1,073		$	(100,594	)	$	46,156

Comprehensive income, net of tax:
Currency translation adjustments	23			23			23			23			(69		)	23
Total other comprehensive income	23			23			23			23			(69		)	23
Comprehensive income	$	46,179		$	51,696		$	47,871		$	1,096		$	(100,663	)	$	46,179

Condensed Consolidating Balance Sheet

December 31, 2013




(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353
Accounts receivable, net	127			14,349			47,631			4,081			—			66,188
Inventories	—			14,660			46,020			4,994			(876		)	64,798
Deferred income tax assets	251			917			5,668			—			—			6,836
Prepaid expenses and other current assets	8,148			66			3,313			799			—			12,326
Total current assets	99,173			29,992			102,632			13,580			(876		)	244,501

Property and equipment, net	9,905			125			229			269			—			10,528
Goodwill	—			66,007			101,540			22,408			—			189,955
Intangible assets, net	—			192,995			1,172,004			30,756			—			1,395,755
Other long-term assets	—			24,107			—			—			—			24,107
Intercompany receivable	596,369			1,919,068			588,046			9,501			(3,112,984		)	—
Investment in subsidiary	1,536,312			735,694			8,259			—			(2,280,265		)	—
Total Assets	$	2,241,759		$	2,967,988		$	1,972,710		$	76,514		$	(5,394,125	)	$	1,864,846

Liabilities and Stockholders' Equity
Current liabilities
Current portion of long-term debt	$	—		$	48,290		$	—		$	—		$	—		$	48,290
Accounts payable	3,063			11,641			34,320			2,523			—			51,547
Accrued interest payable	—			10,781			—			—			—			10,781
Other accrued liabilities	6,144			3,299			10,249			3,753			—			23,445
Total current liabilities	9,207			74,011			44,569			6,276			—			134,063

Long-term debt
Principal amount	—			985,000			—			—			—			985,000
Less unamortized discount	—			(3,489		)	—			—			—			(3,489		)
Long-term debt, net of unamortized discount	—			981,511			—			—			—			981,511

Deferred income tax liabilities	—			55,316			149,652			68			—			205,036
Long term liabilities	—			—			—			302			—			302
Intercompany payable	1,688,618			394,359			992,745			37,262			(3,112,984		)	—
Total Liabilities	1,697,825			1,505,197			1,186,966			43,908			(3,112,984		)	1,320,912

Stockholders' Equity
Preferred share rights	283			—			—			—			—			283
Common stock	520			—			—			—			—			520
Additional paid-in capital	412,910			1,337,706			658,799			23,815			(2,020,320		)	412,910
Treasury stock, at cost - 194 shares	(965		)	—			—			—			—			(965		)
Accumulated other comprehensive income, net of tax	(1,675		)	(1,675		)	(1,675		)	(1,675		)	5,025			(1,675		)
Retained earnings (accumulated deficit)	132,861			126,760			128,620			10,466			(265,846		)	132,861
Total Stockholders' Equity	543,934			1,462,791			785,744			32,606			(2,281,141		)	543,934
Total Liabilities and Stockholders' Equity	$	2,241,759		$	2,967,988		$	1,972,710		$	76,514		$	(5,394,125	)	$	1,864,846

Condensed Consolidating Balance Sheet

March 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors		Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	14,720		$	—		$	—	$	950		$	—		$	15,670
Accounts receivable, net	21			13,875			58,345		812			—			73,053
Inventories	—			11,164			48,474		563			—			60,201
Deferred income tax assets	218			855			5,276		—			—			6,349
Prepaid expenses and other current assets	4,942			93			3,609		256			—			8,900
Total current assets	19,901			25,987			115,704		2,581			—			164,173

Property and equipment, net	9,609			34			253		—			—			9,896
Goodwill	—			66,007			101,539		—			—			167,546
Intangible assets, net	—			193,396			1,179,524		320			—			1,373,240
Other long-term assets	—			24,944			—		—			—			24,944
Intercompany receivable	653,049			1,911,573			415,587		7,316			(2,987,525		)	—
Investment in subsidiary	1,429,775			638,611			7,067		—			(2,075,453		)	—
Total Assets	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,601		$	10,600		$	37,695	$	480		$	—		$	51,376
Accrued interest payable	—			13,894			—		—			—			13,894
Other accrued liabilities	12,694			1,684			16,107		913			—			31,398
Total current liabilities	15,295			26,178			53,802		1,393			—			96,668

Long-term debt
Principal amount	—			978,000			—		—			—			978,000
Less unamortized discount	—			(7,100		)	—		—			—			(7,100		)
Long-term debt, net of unamortized discount	—			970,900			—		—			—			970,900

Deferred income tax liabilities	—			55,291			138,924		73			—			194,288
Intercompany payable	1,619,096			447,419			920,865		145			(2,987,525		)	—
Total Liabilities	1,634,391			1,499,788			1,113,591		1,611			(2,987,525		)	1,261,856

Stockholders' Equity
Preferred share rights	283			—			—		—			—			283
Common stock	513			—			—		—			—			513
Additional paid-in capital	401,691			1,280,945			624,742		1,111			(1,906,798		)	401,691
Treasury stock, at cost - 181 shares	(687		)	—			—		—			—			(687		)
Accumulated other comprehensive loss, net of tax	(104		)	—			—		(104		)	104			(104		)
Retained earnings (accumulated deficit)	76,247			79,819			81,341		7,599			(168,759		)	76,247
Total Stockholders' Equity	477,943			1,360,764			706,083		8,606			(2,075,453		)	477,943
Total Liabilities and Stockholders' Equity	$	2,112,334		$	2,860,552		$	1,819,674	$	10,217		$	(5,062,978	)	$	1,739,799

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2013



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,017			434			7,624			134			—			10,209
Deferred income taxes	(33		)	(37		)	10,336			(5		)	—			10,261
Amortization of deferred financing costs	—			6,023			—			—			—			6,023
Stock-based compensation costs	3,763			—			—			—			—			3,763
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Premium payment on 2010 Senior Notes Tendered	—			(12,768		)	—			—			—			(12,768		)
Amortization of debt discount	—			3,115			—			—			—			3,115
Gain on sale of assets	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(106		)	(474		)	10,714			(1,639		)	—			8,495
Inventories	—			(3,496		)	2,454			(2,096		)	876			(2,262		)
Prepaid expenses and other current assets	(3,206		)	27			296			100			—			(2,783		)
Accounts payable	462			1,041			(3,375		)	587			—			(1,285		)
Accrued liabilities	(6,550		)	(1,498		)	(5,858		)	375			—			(13,531		)
Net cash provided by operating activities	1,614			12,323			66,600			323			—			80,860

Investing Activities
Purchases of property and equipment	(2,555		)	—			—			(103		)	—			(2,658		)
Proceeds from the sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash provided by (used in) investing activities	(2,555		)	(55,215		)	3			(103		)	—			(57,870		)

Financing Activities
Proceeds from the issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Payment of 2010 Senior Notes	—			(201,710		)	—			—			—			(201,710		)
Repayments of long-term debt	—			(147,500		)	—			—			—			(147,500		)
Repayments under revolving credit agreement	—			(45,500		)	—			—			—			(45,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Payment of deferred financing costs	—			(6,933		)	—			—			—			(6,933		)
Proceeds from exercise of stock options	5,738			—			—			—			—			5,738
Excess tax benefits from share-based awards	1,725			—			—			—			—			1,725
Shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	69,683			(5,465		)	(66,603		)	2,385			—			—
Net cash provided by (used in) financing activities	76,868			42,892			(66,603		)	2,385			—			55,542

Effect of exchange rate changes on cash and cash equivalents	—			—			—			151			—			151
Increase in cash and cash equivalents	75,927			—			—			2,756			—			78,683
Cash - beginning of period	14,720			—			—			950			—			15,670
Cash - end of period	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353

Condensed Consolidating Statement of Cash Flows

Nine Months Ended December 31, 2012



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	46,156		$	51,673		$	47,848		$	1,073		$	(100,594	)	$	46,156
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	818			420			8,667			45			—			9,950
Deferred income taxes	143			44			15,796			(4		)	—			15,979
Amortization of deferred financing costs	—			8,220			—			—			—			8,220
Stock-based compensation costs	2,965			—			—			—			—			2,965
Lease termination costs	975			—			—			—			—			975
Amortization of debt discount	—			3,892			—			—			—			3,892
Loss on disposal of equipment	30			—			21			—			—			51
Equity in income of subsidiaries	(50,008		)	(49,280		)	(1,306		)	—			100,594			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(115		)	285			(13,474		)	(214		)	—			(13,518		)
Inventories	—			(1,242		)	(2,104		)	(5		)	—			(3,351		)
Prepaid expenses and other current assets	6,446			(369		)	(627		)	351			—			5,801
Accounts payable	(3,347		)	2,488			14,095			889			—			14,125
Accrued liabilities	(1,071		)	529			9,830			343			—			9,631
Net cash provided by (used in) operating activities	2,992			16,660			78,746			2,478			—			100,876

Investing Activities
Purchases of property and equipment	(8,922		)	—			—			—			—			(8,922		)
Proceeds from sale of property and equipment	—			—			15			—			—			15
Proceeds from the sale of the Phazyme brand	—			—			21,700			—			—			21,700
Acquisition of GSK purchase price adjustments	—			—			(226		)	—			—			(226		)
Intercompany activity, net	(226		)	—			226			—			—			—
Net cash (used in) provided by investing activities	(9,148		)	—			21,715			—			—			12,567

Financing Activities
Repayment of long-term debt	—			(167,500		)	—			—			—			(167,500		)
Repayments under revolving credit agreement	—			(8,000		)	—			—			—			(8,000		)
Borrowings under revolving credit agreement	—			48,000			—			—			—			48,000
Proceeds from exercise of stock options	5,460			—			—			—			—			5,460
Intercompany activity, net	(8,647		)	110,840			(100,461		)	(1,732		)	—			—
Net cash used in financing activities	(3,187		)	(16,660		)	(100,461		)	(1,732		)	—			(122,040		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			13			—			13
(Decrease) increase in cash and cash equivalents	(9,343		)	—			—			759			—			(8,584		)
Cash - beginning of period	18,221			—			—			794			—			19,015
Cash - end of period	$	8,878		$	—		$	—		$	1,553		$	—		$	10,431

Business and Basis of Presentation (Property and Equipment) (Details)

9 Months Ended

Dec. 31, 2013

Machinery

Property, Plant and Equipment [Line Items]

Property and equipment, useful lives

5 years

Computer equipment and software

Property, Plant and Equipment [Line Items]

Property and equipment, useful lives

3 years

Furniture and fixtures

Property, Plant and Equipment [Line Items]

Property and equipment, useful lives

7 years

Leasehold improvements

Property, Plant and Equipment [Line Items]

Property and equipment, useful lives

^[1]

[1]	Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%		100.00%
Term of original maturities, cash equivalents, up to and including			3 months
Shipping costs, and handling and storage costs	$ 7.6	$ 7.6	$ 23.3	$ 23.1

- Definition

Cost incurred during the reporting period in transporting goods and services to customers. Includes freight-out costs.

+ References+ Details

Acquisitions (Care Pharmaceuticals Pty Ltd.) (Details) (USD $)	9 Months Ended		9 Months Ended
	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013 Care Pharma	Jul. 02, 2013 Care Pharma
Purchase Price
Cash acquired				$ 1,546,000
Accounts receivable				1,658,000
Inventories				2,465,000
Prepaids and other current assets				647,000
Property, plant and equipment				163,000
Goodwill	189,955,000	167,546,000		23,122,000
Intangible assets				31,502,000
Total assets acquired				61,103,000
Accounts payable				1,537,000
Accrued expenses				2,505,000
Other long term liabilities				300,000
Total liabilities assumed				4,342,000
Net assets acquired				56,761,000
Indefinite-lived intangible assets				29,800,000
Finite-lived intangibles				1,700,000
Purchased amortizable intangible assets, weighted average useful life			15 years 1 month 6 days
Amortizable intangible assets, weighted average remaining life	13 years 9 months 1 day		14 years 1 month 0 days
Goodwill, Acquired During Period	$ 23,122,000

Divestitures (Details) (Sale of Phazyme Brand, USD $) In Thousands, unless otherwise specified	Oct. 31, 2012
Sale of Phazyme Brand
Components of assets sold:
Inventory	$ 220
Prepaid expenses	100
Trade names	15,604
Goodwill	$ 6,382

Divestitures (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jan. 04, 2013 Sale of Phazyme Brand	Oct. 31, 2012 Sale of Phazyme Brand
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from the sale of the Phazyme brand	$ 0	$ 21,700	$ 600	$ 21,700

Accounts Receivable (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 75,734	$ 80,361
Less allowances for discounts, returns and uncollectible accounts	(9,546)	(7,308)
Accounts receivable, net	66,188	73,053
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	74,025	79,746
Other Receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,709	$ 615

Inventories (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 1,455,000	$ 1,875,000
Finished goods	63,343,000	58,326,000
Inventories	64,798,000	60,201,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 2,600,000	$ 1,300,000

- Definition

Amount of valuation reserve for inventory.

+ References+ Details

Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013
Components of Property and Equipment
Property and equipment, gross	$ 17,314,000		$ 17,314,000		$ 14,362,000
Accumulated depreciation	(6,786,000)		(6,786,000)		(4,466,000)
Property and equipment, net	10,528,000		10,528,000		9,896,000
Depreciation	1,100,000	400,000	2,200,000	1,000,000
Machinery
Components of Property and Equipment
Property and equipment, gross	1,870,000		1,870,000		1,580,000
Computer equipment and software
Components of Property and Equipment
Property and equipment, gross	8,886,000		8,886,000		6,559,000
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	1,826,000		1,826,000		1,510,000
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	4,732,000		4,732,000		4,713,000
Impairment of assets				$ 100,000

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).

+ References+ Details

Goodwill (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2013 OTC Healthcare	Dec. 31, 2013 Household Cleaning	Jul. 02, 2013 Care Pharma
Goodwill [Roll Forward]
Goodwill beginning balance	$ 167,546	$ 160,157	$ 7,389	$ 23,122
Additions	23,122	23,122	0
Effects of foreign currency exchange rates	(713)	(713)	0
Goodwill ending balance	$ 189,955	$ 182,566	$ 7,389	$ 23,122

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2013
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, ending balance	$ 1,272,644	$ 1,272,644
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions	2,600	8,019
Finite-lived intangibles, accumulated amortization, effects of foreign exchange rates		(2)
Intangible Assets, Gross [Abstract]
Intangible assets, gross, beginning balance		1,446,942
Intangible assets, additions		31,502
Intangible assets, reductions		(158)
Intangible assets, effects of foreign currency exchange rate		(970)
Intangible assets, gross, ending balance	1,477,316	1,477,316
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, beginning balance		73,702
Intangible assets, accumulated amortization, additions	2,600	8,019
Intangible assets, accumulated amortization, reductions		(158)
Intangible assets, accumulated amortization, ending balance	81,561	81,561
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	123,111	123,111
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	1,395,755	1,395,755	1,373,240
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning balance		1,243,718
Indefinite-lived intangibles, additions		29,845
Indefinite-lived intangibles, reductions		0
Indefinite-lived intangibles, effects of foreign currency exchange rate		(919)
Indefinite-lived intangibles, ending balance	1,272,644	1,272,644
Finite Lived Trademarks
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning balance		203,066
Finite-lived intangibles, additions		1,657
Finite-lived intangibles, reductions		0
Finite-lived intangibles, effects of foreign currency exchange rate		(51)
Finite-lived intangibles, gross, ending balance	204,672	204,672
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning balance		73,544
Intangible assets, accumulated amortization, additions		8,019
Finite-lived intangibles, accumulated amortization, reductions		0
Finite-lived intangibles, accumulated amortization, effects of foreign exchange rates		(2)
Finite-lived intangibles, accumulated amortization, ending balance	81,561	81,561
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions		8,019
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	123,111	123,111
Noncompete Agreements
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning balance		158
Finite-lived intangibles, additions		0
Finite-lived intangibles, reductions		(158)
Finite-lived intangibles, effects of foreign currency exchange rate		0
Finite-lived intangibles, gross, ending balance	0	0
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning balance		158
Intangible assets, accumulated amortization, additions		0
Finite-lived intangibles, accumulated amortization, reductions		(158)
Finite-lived intangibles, accumulated amortization, effects of foreign exchange rates		0
Finite-lived intangibles, accumulated amortization, ending balance	0	0
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions		0
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	$ 0	$ 0

Intangible Assets (Expected Amortization Expense) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, weighted average remaining period		13 years 9 months 1 day
Amortization of intangible assets	$ 2,600	$ 8,019
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2014 (Remaining three months ending March 31, 2014)	2,235	2,235
2015	8,949	8,949
2016	8,949	8,949
2017	8,949	8,949
2018	8,949	8,949
Thereafter	85,080	85,080
Intangible assets, net	$ 123,111	$ 123,111
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives		3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives		30 years

Other Accrued Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2013
Payables and Accruals [Abstract]
Accrued marketing costs	$ 11,845	$ 17,187
Accrued compensation costs	5,378	8,847
Accrued broker commissions	941	1,028
Income taxes payable	0	493
Accrued professional fees	3,794	1,846
Deferred rent	1,254	1,268
Accrued lease termination costs	180	729
Other accrued liabilities	53	0
Other accrued liabilities	$ 23,445	$ 31,398

Long-Term Debt (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended											0 Months Ended	3 Months Ended	9 Months Ended										0 Months Ended			3 Months Ended	9 Months Ended									3 Months Ended		0 Months Ended		3 Months Ended				9 Months Ended		0 Months Ended				0 Months Ended
Long-Term Debt (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 17, 2013	Mar. 31, 2013	Jan. 31, 2012	Dec. 31, 2013 2012 Senior Notes	Jan. 31, 2012 2012 Senior Notes	Dec. 17, 2013 2013 Senior Notes	Jan. 31, 2012 Term Loan and ABL Revolver 2012	Jun. 30, 2013 Revolving Credit Facility 2010 Revolving Credit Facility	Sep. 30, 2012 Revolving Credit Facility 2010 Revolving Credit Facility	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver	Jun. 30, 2013 Revolving Credit Facility 2012 ABL Revolver	Dec. 31, 2013 Revolving Credit Facility 2012 ABL Revolver	Sep. 30, 2012 Revolving Credit Facility 2012 ABL Revolver	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver LIBOR	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver LIBOR Minimum	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver LIBOR Maximum	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver Base Rate	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver Base Rate Minimum	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver Base Rate Maximum	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver Base Rate Federal Funds Rate	Jan. 31, 2012 Revolving Credit Facility 2012 ABL Revolver Base Rate LIBOR	Dec. 17, 2013 Senior Notes 2010 Senior Notes	Nov. 01, 2010 Senior Notes 2010 Senior Notes	Mar. 24, 2010 Senior Notes 2010 Senior Notes	Dec. 31, 2013 Senior Notes 2010 Senior Notes	Dec. 31, 2013 Senior Notes 2010 Senior Notes	Mar. 31, 2011 Senior Notes 2010 Senior Notes	Jan. 31, 2012 Senior Notes 2012 Senior Notes	Jan. 31, 2012 Senior Notes 2012 Senior Notes Prior to February 1, 2016	Jan. 31, 2012 Senior Notes 2012 Senior Notes Prior to February 1, 2015	Jan. 31, 2012 Senior Notes 2012 Senior Notes Upon Change in Control	Dec. 17, 2013 Senior Notes 2013 Senior Notes	Dec. 31, 2013 Senior Notes 2013 Senior Notes Prior to December 15, 2016	Dec. 31, 2013 Senior Notes 2013 Senior Notes On Or After December 15, 2016	Mar. 31, 2013 Term Loans Amended 2012 Term Loan	Feb. 21, 2013 Term Loans Amended 2012 Term Loan	Feb. 21, 2013 Term Loans Amended 2012 Term Loan LIBOR	Jan. 31, 2012 Term Loans 2012 Term Loan	Mar. 31, 2013 Term Loans 2012 Term Loan	Dec. 31, 2012 Term Loans 2012 Term Loan	Sep. 30, 2012 Term Loans 2012 Term Loan	Jun. 30, 2012 Term Loans 2012 Term Loan	Dec. 31, 2013 Term Loans 2012 Term Loan	Dec. 31, 2012 Term Loans 2012 Term Loan	Jan. 31, 2012 Term Loans 2012 Term Loan LIBOR Minimum	Jan. 31, 2012 Term Loans 2012 Term Loan Base Rate	Jan. 31, 2012 Term Loans 2012 Term Loan Base Rate Federal Funds Rate	Jan. 31, 2012 Term Loans 2012 Term Loan Base Rate LIBOR	Jan. 16, 2014 Subsequent Event Senior Notes 2010 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount																												$ 150,000,000				$ 250,000,000				$ 400,000,000						$ 660,000,000
Debt instrument, stated interest rate																												8.25%				8.125%				5.375%
Debt instrument, increase, additional borrowings																											100,000,000
Debt instrument, unamortized discount	3,489,000		3,489,000			7,100,000																						2,200,000
Debt instrument, unamortized premium																											300,000
Proceeds from issuance of long-term debt																											100,300,000	147,800,000														650,100,000
Debt instrument, effective interest rate																															8.50%
Percentage of subsidiary owned					100.00%		100.00%
Premium percentage																										6.33%
Repayments of debt			201,710,000	0																						(201,700,000)																											48,300,000
Loss on extinguishment of debt	15,012,000	0	15,012,000	0																									15,000,000										1,400,000
Non-cash acceleration expense, before tax																																												7,700,000				3,000,000
Non-cash acceleration expense, increase (decrease)																																											(1,100,000)	1,100,000	(700,000)	(1,200,000)		3,000,000
Non-cash acceleration expense, net of tax																																											700,000	700,000	500,000	700,000		1,900,000
Non-cash acceleration expense, effect on diluted share																																											$ 0.01	$ 0.01	$ 0.01	$ 0.02		$ 0.03
Additional loss on extinguishment of debt																																																					3,300,000
Tendered debt																																																					48,300,000
Repayments of debt premium			12,768,000	0																										(12,800,000)
Write off of deferred debt financing costs																														1,700,000
Write off of debt discount																														500,000
Debt issuance costs capitalized									12,600,000	6,700,000	20,600,000
Debt instrument, maturity term														5 years																												7 years
Line of credit facility, maximum borrowing capacity														50,000,000	95,000,000		75,000,000
Line of credit facility, increase in borrowing capacity												20,000,000	25,000,000
Decrease in interest rate															0.25%
Debt instrument, discount, percentage																																										1.50%
Debt instrument, basis spread on variable rate																																									2.75%								1.00%
Debt instrument, reference rate floor																																								1.00%
Debt instrument, basis spread on variable rate, fixed component																								0.50%	1.00%																									2.00%	0.50%	1.00%
Debt instrument, average interest rate during period																																															4.00%
Debt instrument, quarterly payment, percent of original principal amount																																										0.25%
Debt instrument, variable rate																		1.75%			0.75%
Debt instrument, conditional variable rate																			2.00%	2.25%		1.00%	1.25%
Line of credit facility, commitment fee percentage														0.50%
Line of credit facility, conditional commitment fee percentage														0.375%
Line of credit facility, interest rate at period end																2.00%
Unamortized debt issuance costs	24,100,000		24,100,000
Unamortized debt issuance expense and discount								10,400,000								1,400,000													500,000	500,000																	8,700,000
Debt instrument, redemption price, percentage of principal amount																																	100.00%	108.125%	101.00%		100.00%	105.375%
Debt instrument, percentage of principal amount eligible for redemption																																		35.00%			35.00%
Repayments of long-term debt			$ 147,500,000	$ 167,500,000												$ 4,500,000

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013	Mar. 24, 2010
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,033,290,000	$ 978,000,000
Less: unamortized discount	(3,489,000)	(7,100,000)
Current portion of long-term debt	48,290,000	0
Principal amount	985,000,000	978,000,000
Long-term debt, net of unamortized discount	981,511,000	970,900,000
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	400,000,000	0
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	250,000,000	250,000,000
Senior Notes \| 2010 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	48,290,000	250,000,000
Less: unamortized discount			(2,200,000)
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	297,500,000	445,000,000
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt, gross	$ 37,500,000	$ 33,000,000

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Debt Disclosure [Abstract]
2014 (remaining three months ending March 31, 2014)	$ 48,290,000
2015	0
2016	0
2017	37,500,000
2018	0
Thereafter	947,500,000
Long-term debt, gross	$ 1,033,290,000	$ 978,000,000

Fair Value Measurements (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Senior Notes \| 2013 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 400,000,000
Senior Notes \| 2012 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	250,000,000
Senior Notes \| 2010 Senior Notes \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	48,300,000.0	250,000,000.0
Senior Notes \| Nonrecurring \| Fair Value, Inputs, Level 2 \| 2013 Senior Notes \| Market Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	403,000,000
Senior Notes \| Nonrecurring \| Fair Value, Inputs, Level 2 \| 2012 Senior Notes \| Market Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	279,100,000	281,900,000
Senior Notes \| Nonrecurring \| Fair Value, Inputs, Level 2 \| 2010 Senior Notes \| Market Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	51,100,000	271,900,000
Term Loans \| 2012 Term Loan \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	297,500,000	445,000,000.0
Term Loans \| Nonrecurring \| Fair Value, Inputs, Level 2 \| 2012 Term Loan \| Market Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	299,000,000	451,100,000
Revolving Credit Facility \| 2012 ABL Revolver \| Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$ 37,500,000	$ 33,000,000

Stockholders' Equity (Details) (USD $)			3 Months Ended	9 Months Ended
Stockholders' Equity (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013 Restricted Shares	Dec. 31, 2013 Restricted Shares
Class of Stock [Line Items]
Common stock, shares authorized	250,000,000	250,000,000
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned	1
Restricted stock repurchased during period, shares			2,549	13,275
Restricted stock acquired, average cost per share			$ 27.81

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2013
Accumulated Other Comprehensive Income [Abstract]
Cumulative translation adjustment	$ (1,675)	$ (104)
Total accumulated other comprehensive loss, net of tax	$ (1,675)	$ (104)

- Definition

Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.

+ References+ Details

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References+ Details

Earnings Per Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Numerator
Net income	$ 3,130	$ 12,257	$ 56,614	$ 46,156
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	51,806	50,686	51,498	50,465
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors (in shares)	639	837	738	820
Denominator for diluted earnings per share (in shares)	52,445	51,523	52,236	51,285
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.06	$ 0.24	$ 1.10	$ 0.91
Diluted net earnings per share (in USD per share)	$ 0.06	$ 0.24	$ 1.08	$ 0.90

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Earnings Per Share Antidilutive Securities (Details) (Outstanding Stock Awards) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares (fewer than 0.1 million shares for the three and nine months ended December 31, 2012)	0.2	0.1	0.2	0.1

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Share-Based Compensation (Narrative) (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended										0 Months Ended		9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 Restricted Stock and Restricted Stock Units (RSUs)	Dec. 31, 2012 Restricted Stock and Restricted Stock Units (RSUs)	Dec. 31, 2013 Restricted Stock and Restricted Stock Units (RSUs) Minimum	Dec. 31, 2013 Restricted Stock and Restricted Stock Units (RSUs) Maximum	Dec. 31, 2013 Restricted Stock Units (RSUs)	Dec. 31, 2012 Restricted Stock Units (RSUs)	Dec. 31, 2013 Stock Options Minimum	Dec. 31, 2013 Stock Options Maximum	Nov. 05, 2013 Employee Restricted Stock Units (RSUs)	May 14, 2013 Employee Restricted Stock Units (RSUs)	Dec. 31, 2013 Employee Restricted Stock Units (RSUs)	May 14, 2013 Employee Stock Options	Jun. 30, 2013 Director Restricted Stock Units (RSUs)	Dec. 31, 2013 Director Restricted Stock Units (RSUs)	May 14, 2013 Group One Employee Restricted Stock Units (RSUs)	May 14, 2013 Group Two Employee Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan	5,000,000		5,000,000
Share-based compensation costs charged against income	$ 1.3	$ 1.0	$ 3.8	$ 3.0
Tax benefit recognized from share-based compensation expense	0.4	0.3	1.1	0.9
Restricted Shares
Award vesting period							3 years	5 years			3 years	5 years			3 years	3 years		1 year	3 years	3 years
Restricted common stock units granted in period, shares					126,600	128,900							6,000	113,637			7,004		55,637	58,000
Granted, weighted-average grant-date fair value (in USD per share)					$ 30.19	$ 13.59			$ 30.19	$ 13.59
Options, Additional Disclosures:
Award exercisability period, from date of grant												10 years				10 years
Options granted in period																227,672
Percentage of options vesting annually																33.30%				33.30%
Options granted, weighted-average grant-date fair value (in USD per share)			$ 13.94	$ 6.03												$ 29.94
Options exercised, aggregate intrinsic value			13.7
Options granted, aggregate intrinsic value			1.3
Unrecognized compensation costs related to nonvested awards	5.0		5.0
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition			0 years 11 months
Total fair value of vested shares			3.2	2.1
Cash received from exercise of stock options			5.7	5.4
Tax benefit realized from exercise of stock options			$ 1.7	$ 9.3
Shares available for issuance under the Plan	1,600,000		1,600,000

Share-Based Compensation (Restricted Shares and Restricted Stock Units Activity) (Details) (Restricted Stock and Restricted Stock Units (RSUs), USD $)	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock and Restricted Stock Units (RSUs)
Shares
Outstanding, beginning of period	421,300	363,400
Granted	126,600	128,900
Vested and issued	(59,700)	(27,000)
Forfeited	(5,600)	(12,300)
Outstanding, end of period	482,600	453,000
Vested, end of period	83,100	70,400
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 11.01	$ 9.92
Granted, weighted-average grant-date fair value (in USD per share)	$ 30.19	$ 13.59
Vested and issued, weighted-average grant-date fair value (in USD per share)	$ 8.42	$ 7.16
Forfeited, weighted-average grant-date fair value (in USD per share)	$ 15.11	$ 10.69
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	$ 16.32	$ 11.11
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 9.63	$ 8.52

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $)	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	48.00%	44.00%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years 6 months
Risk-free rate	1.30%	1.20%

Share-Based Compensation (Stock Option Activity) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Shares
Outstanding, beginning of period (in shares)	1,386,400	1,745,400
Granted (in shares)	227,700	444,900
Exercised (in shares)	(589,900)	(708,500)
Forfeited or expired (in shares)	(14,200)	(17,400)
Outstanding, end of period (in shares)	1,010,000	1,464,400
Exercisable, end of period (in shares)	172,100	332,400
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 10.43	$ 8.44
Granted, weighted-average exercise price (in USD per share)	$ 29.94	$ 13.36
Exercised, weighted-average exercise price (in USD per share)	$ 9.73	$ 7.71
Forfeited or expired, weighted-average exercise price (in USD per share)	$ 14.56	$ 11.21
Outstanding, end of period, weighted-average exercise price (in USD per share)	$ 15.18	$ 10.26
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 11.34	$ 9.99
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 7 months	7 years 8 months 0 days
Exercisable, end of period, weighted-average remaining contractual term	6 years 9 months 18 days	6 years 10 months 0 days
Outstanding, end of period, aggregate intrinsic value	$ 20,828	$ 11,330
Exercisable, end of period, aggregate intrinsic value	$ 4,210	$ 2,248

Income Taxes (Narrative) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013
Income Tax Disclosure [Abstract]
Effective income tax rate	25.20%	38.90%	24.60%	38.90%
Income tax benefit adjustment	$ 0.4		$ 8.9
Net operating loss carryforwards	1.0		1.0
Operating loss carryforwards, limitation on use, annual amount	0.2		0.2
Increase in uncertain tax liability			0.2
Uncertain tax liability	$ 1.2		$ 1.2		$ 1.0

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended	1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 Facilities	Dec. 31, 2012 New York	May 31, 2012 Arkansas	Dec. 31, 2013 Equipment
Operating Leased Assets [Line Items]
Operating lease, term						5 years 6 months	3 years
2014 (Remaining three months ending March 31, 2014)	$ 494,000		$ 494,000		$ 459,000			$ 35,000
2015	1,185,000		1,185,000		1,049,000			136,000
2016	1,129,000		1,129,000		994,000			135,000
2017	1,091,000		1,091,000		1,023,000			68,000
2018	1,044,000		1,044,000		1,044,000			0
Thereafter	0		0		0			0
Total future minimum payments due	4,943,000		4,943,000		4,569,000			374,000
Operating leases, rent expense	$ 400,000	$ 300,000	$ 1,200,000	$ 900,000

Commitments and Contingencies (Long-term Supply Agreement) (Details) (Third-party Manufacturing, USD $) In Thousands, unless otherwise specified	0 Months Ended
	Nov. 01, 2009	Dec. 31, 2013
Third-party Manufacturing
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2014 (Remaining three months ending March 31, 2014)		$ 281
2015		1,105
2016		1,074
2017		1,044
2018		1,013
Thereafter		1,542
Total purchase commitment		$ 6,059

Concentrations of Risk (Details)	3 Months Ended		9 Months Ended
Concentrations of Risk (Details)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013 brand	Dec. 31, 2012
Concentration Risk [Line Items]
Number of third-party manufacturers	58	62	58	62
Sales \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	41.10%	40.30%	41.70%	40.70%
Number of highest selling brands comprising group against which concentration risk is measured			5
Sales \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	20.40%	21.50%	19.70%	21.30%
Number of customers exceeding concentration risk benchmark			1	1
Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			86.30%	77.10%
Number of third-party manufacturers with long-term contracts			21	24
Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			20.20%

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information, Profit (Loss):
Net sales	$ 145,054	$ 159,492	$ 454,159	$ 466,735
Other revenues	1,158	740	3,466	2,349
Total revenues	146,212	160,232	457,625	469,084
Cost of sales	64,403	75,235	197,614	209,938
Gross profit	81,809	84,997	260,011	259,146
Advertising and promotion	25,570	23,538	70,754	67,371
Contribution margin	56,239	61,459	189,257	191,775
Other operating expenses	15,781	14,737	45,596	50,064
Operating income	40,458	46,722	143,661	141,711
Other expense	36,272	26,661	68,616	66,169
Income before income taxes	4,186	20,061	75,045	75,542
Provision for income taxes	1,056	7,804	18,431	29,386
Net income	3,130	12,257	56,614	46,156
OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	125,448	138,858	390,670	402,633
Other revenues	150	175	462	520
Total revenues	125,598	139,033	391,132	403,153
Cost of sales	49,042	59,381	149,378	160,249
Gross profit	76,556	79,652	241,754	242,904
Advertising and promotion	24,830	22,410	68,375	62,309
Contribution margin	51,726	57,242	173,379	180,595
Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	19,606	20,634	63,489	64,102
Other revenues	1,008	565	3,004	1,829
Total revenues	20,614	21,199	66,493	65,931
Cost of sales	15,361	15,854	48,236	49,689
Gross profit	5,253	5,345	18,257	16,242
Advertising and promotion	740	1,128	2,379	5,062
Contribution margin	$ 4,513	$ 4,217	$ 15,878	$ 11,180
Geographic Concentration Risk \| Sales \| United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	85.70%	89.10%	87.20%	89.90%
Geographic Concentration Risk \| Sales \| Canada
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	8.30%	8.10%	7.80%	7.50%

Business Segments (Revenue by Product) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenue from External Customer [Line Items]
Revenues	$ 146,212	$ 160,232	$ 457,625	$ 469,084
OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	125,598	139,033	391,132	403,153
OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Revenues	25,903	27,946	84,634	81,727
OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Revenues	34,330	37,424	89,548	94,197
OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	20,190	24,977	64,841	74,510
OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	19,400	19,702	63,519	63,109
OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Revenues	9,797	11,496	40,223	41,578
OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Revenues	11,408	12,953	35,845	36,032
OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Revenues	4,570	4,535	12,522	12,000
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	$ 20,614	$ 21,199	$ 66,493	$ 65,931

Business Segments (Assets by Segment) (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2013
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 189,955	$ 167,546
Indefinite-lived intangibles	1,272,644
Finite-lived intangibles	123,111
Intangible assets, net (excluding goodwill)	1,395,755	1,373,240
Intangible assets, net (including goodwill)	1,585,710
OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	182,566	160,157
Indefinite-lived intangibles	1,152,824
Finite-lived intangibles	96,508
Intangible assets, net (excluding goodwill)	1,249,332
Intangible assets, net (including goodwill)	1,431,898
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	7,389	7,389
Indefinite-lived intangibles	119,820
Finite-lived intangibles	26,603
Intangible assets, net (excluding goodwill)	146,423
Intangible assets, net (including goodwill)	$ 153,812

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Revenues
Net sales	$ 145,054,000	$ 159,492,000	$ 454,159,000	$ 466,735,000
Other revenues	1,158,000	740,000	3,466,000	2,349,000
Total revenues	146,212,000	160,232,000	457,625,000	469,084,000
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	64,403,000	75,235,000	197,614,000	209,938,000
Gross profit	81,809,000	84,997,000	260,011,000	259,146,000
Operating Expenses
Advertising and promotion	25,570,000	23,538,000	70,754,000	67,371,000
General and administrative	12,137,000	11,378,000	35,390,000	40,114,000
Depreciation and amortization	3,644,000	3,359,000	10,206,000	9,950,000
Total operating expenses	41,351,000	38,275,000	116,350,000	117,435,000
Operating income	40,458,000	46,722,000	143,661,000	141,711,000
Other (income) expense
Interest income	(16,000)	(4,000)	(44,000)	(9,000)
Interest expense	21,276,000	26,665,000	53,648,000	66,178,000
Loss on extinguishment of debt	15,012,000	0	15,012,000	0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	36,272,000	26,661,000	68,616,000	66,169,000
Income before income taxes	4,186,000	20,061,000	75,045,000	75,542,000
Provision (benefit) for income taxes	1,056,000	7,804,000	18,431,000	29,386,000
Net income	3,130,000	12,257,000	56,614,000	46,156,000
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,694,000)	(1,000)	(1,571,000)	23,000
Total other comprehensive (loss) income	(2,694,000)	(1,000)	(1,571,000)	23,000
Comprehensive income	436,000	12,256,000	55,043,000	46,179,000
Prestige Brands Holdings, Inc.
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	600,000
Revenues
Net sales	0	0	0	0
Other revenues	0	0	0	0
Total revenues	0	0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	165,000	952,000	2,555,000	3,676,000
Depreciation and amortization	983,000	549,000	2,017,000	818,000
Total operating expenses	1,148,000	1,501,000	4,572,000	4,494,000
Operating income	(1,148,000)	(1,501,000)	(4,572,000)	(4,494,000)
Other (income) expense
Interest income	(12,305,000)	33,000	(37,296,000)	(24,337,000)
Interest expense	8,671,000	8,735,000	25,965,000	26,147,000
Loss on extinguishment of debt	0		0
Equity in (income) loss of subsidiaries	(1,148,000)	(18,531,000)	(51,347,000)	(50,008,000)
Total other expense	(4,782,000)	(9,763,000)	(62,678,000)	(48,198,000)
Income before income taxes	3,634,000	8,262,000	58,106,000	43,704,000
Provision (benefit) for income taxes	504,000	(3,995,000)	1,492,000	(2,452,000)
Net income	3,130,000	12,257,000	56,614,000	46,156,000
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,694,000)	(1,000)	(1,571,000)	23,000
Total other comprehensive (loss) income	(2,694,000)	(1,000)	(1,571,000)	23,000
Comprehensive income	436,000	12,256,000	55,043,000	46,179,000
Prestige Brands, Inc., the issuer
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	(48,100,000)
Corrections adjustment for cumulative adjustment	1,000,000
Revenues
Net sales	25,689,000	25,345,000	75,339,000	75,294,000
Other revenues	75,000	79,000	210,000	220,000
Total revenues	25,764,000	25,424,000	75,549,000	75,514,000
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	9,361,000	9,877,000	28,157,000	28,493,000
Gross profit	16,403,000	15,547,000	47,392,000	47,021,000
Operating Expenses
Advertising and promotion	2,066,000	3,032,000	9,254,000	8,917,000
General and administrative	2,132,000	1,585,000	5,256,000	5,020,000
Depreciation and amortization	149,000	140,000	434,000	420,000
Total operating expenses	4,347,000	4,757,000	14,944,000	14,357,000
Operating income	12,056,000	10,790,000	32,448,000	32,664,000
Other (income) expense
Interest income	(14,437,000)	(41,552,000)	(42,765,000)	(63,573,000)
Interest expense	21,276,000	35,394,000	53,648,000	92,320,000
Loss on extinguishment of debt	15,012,000		15,012,000
Equity in (income) loss of subsidiaries	(6,845,000)	(8,407,000)	(41,997,000)	(49,280,000)
Total other expense	15,006,000	(14,565,000)	(16,102,000)	(20,533,000)
Income before income taxes	(2,950,000)	25,355,000	48,550,000	53,197,000
Provision (benefit) for income taxes	(2,541,000)	6,593,000	1,609,000	1,524,000
Net income	(409,000)	18,762,000	46,941,000	51,673,000
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,694,000)	(1,000)	(1,571,000)	23,000
Total other comprehensive (loss) income	(2,694,000)	(1,000)	(1,571,000)	23,000
Comprehensive income	(3,103,000)	18,761,000	45,370,000	51,696,000
Combined Subsidiary Guarantors
Revenues
Net sales	113,685,000	132,881,000	364,468,000	387,815,000
Other revenues	1,160,000	724,000	3,454,000	2,310,000
Total revenues	114,845,000	133,605,000	367,922,000	390,125,000
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	53,750,000	65,172,000	165,252,000	181,382,000
Gross profit	61,095,000	68,433,000	202,670,000	208,743,000
Operating Expenses
Advertising and promotion	21,359,000	19,997,000	57,751,000	57,326,000
General and administrative	8,967,000	8,734,000	25,782,000	30,802,000
Depreciation and amortization	2,440,000	2,658,000	7,625,000	8,667,000
Total operating expenses	32,766,000	31,389,000	91,158,000	96,795,000
Operating income	28,329,000	37,044,000	111,512,000	111,948,000
Other (income) expense
Interest income	(731,000)	162,000	(1,441,000)	162,000
Interest expense	18,061,000	23,951,000	54,082,000	35,613,000
Loss on extinguishment of debt	0		0
Equity in (income) loss of subsidiaries	(999,000)	(393,000)	(2,867,000)	(1,306,000)
Total other expense	16,331,000	23,720,000	49,774,000	34,469,000
Income before income taxes	11,998,000	13,324,000	61,738,000	77,479,000
Provision (benefit) for income taxes	2,720,000	5,030,000	14,459,000	29,631,000
Net income	9,278,000	8,294,000	47,279,000	47,848,000
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,694,000)	(1,000)	(1,571,000)	23,000
Total other comprehensive (loss) income	(2,694,000)	(1,000)	(1,571,000)	23,000
Comprehensive income	6,584,000	8,293,000	45,708,000	47,871,000
Combined Non-Guarantor Subsidiaries
Revenues
Net sales	7,502,000	1,266,000	16,174,000	3,626,000
Other revenues	10,000	276,000	1,112,000	1,270,000
Total revenues	7,512,000	1,542,000	17,286,000	4,896,000
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	2,325,000	525,000	6,461,000	1,514,000
Gross profit	5,187,000	1,017,000	10,825,000	3,382,000
Operating Expenses
Advertising and promotion	2,145,000	509,000	3,749,000	1,128,000
General and administrative	873,000	107,000	1,797,000	616,000
Depreciation and amortization	72,000	12,000	130,000	45,000
Total operating expenses	3,090,000	628,000	5,676,000	1,789,000
Operating income	2,097,000	389,000	5,149,000	1,593,000
Other (income) expense
Interest income	(6,000)	(62,000)	(30,000)	(163,000)
Interest expense	731,000	0	1,441,000	0
Loss on extinguishment of debt	0		0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	725,000	(62,000)	1,411,000	(163,000)
Income before income taxes	1,372,000	451,000	3,738,000	1,756,000
Provision (benefit) for income taxes	373,000	176,000	871,000	683,000
Net income	999,000	275,000	2,867,000	1,073,000
Comprehensive (loss) income, net of tax:
Currency translation adjustments	(2,694,000)	(1,000)	(1,571,000)	23,000
Total other comprehensive (loss) income	(2,694,000)	(1,000)	(1,571,000)	23,000
Comprehensive income	(1,695,000)	274,000	1,296,000	1,096,000
Eliminations
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	(47,500,000)
Revenues
Net sales	(1,822,000)	0	(1,822,000)	0
Other revenues	(87,000)	(339,000)	(1,310,000)	(1,451,000)
Total revenues	(1,909,000)	(339,000)	(3,132,000)	(1,451,000)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	(1,033,000)	(339,000)	(2,256,000)	(1,451,000)
Gross profit	(876,000)	0	(876,000)	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	0	0	0	0
Operating income	(876,000)	0	(876,000)	0
Other (income) expense
Interest income	27,463,000	41,415,000	81,488,000	87,902,000
Interest expense	(27,463,000)	(41,415,000)	(81,488,000)	(87,902,000)
Loss on extinguishment of debt	0		0
Equity in (income) loss of subsidiaries	8,992,000	27,331,000	96,211,000	100,594,000
Total other expense	8,992,000	27,331,000	96,211,000	100,594,000
Income before income taxes	(9,868,000)	(27,331,000)	(97,087,000)	(100,594,000)
Provision (benefit) for income taxes	0	0	0	0
Net income	(9,868,000)	(27,331,000)	(97,087,000)	(100,594,000)
Comprehensive (loss) income, net of tax:
Currency translation adjustments	8,082,000	3,000	4,713,000	(69,000)
Total other comprehensive (loss) income	8,082,000	3,000	4,713,000	(69,000)
Comprehensive income	$ (1,786,000)	$ (27,328,000)	$ (92,374,000)	$ (100,663,000)

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	$ 94,353	$ 15,670	$ 10,431	$ 19,015
Accounts receivable, net	66,188	73,053
Inventories	64,798	60,201
Deferred income tax assets	6,836	6,349
Prepaid expenses and other current assets	12,326	8,900
Total current assets	244,501	164,173
Property and equipment, net	10,528	9,896
Goodwill	189,955	167,546
Intangible assets, net	1,395,755	1,373,240
Other long-term assets	24,107	24,944
Intercompany receivable	0	0
Investment in subsidiary	0	0
Total Assets	1,864,846	1,739,799
Current liabilities
Current portion of long-term debt	48,290	0
Accounts payable	51,547	51,376
Accrued interest payable	10,781	13,894
Other accrued liabilities	23,445	31,398
Total current liabilities	134,063	96,668
Long-term debt
Principal amount	985,000	978,000
Less unamortized discount	(3,489)	(7,100)
Long-term debt, net of unamortized discount	981,511	970,900
Deferred income tax liabilities	205,036	194,288
Long term liabilities	302
Intercompany payable	0	0
Total Liabilities	1,320,912	1,261,856
Stockholders' Equity
Preferred share rights	283	283
Common stock	520	513
Additional paid-in capital	412,910	401,691
Treasury stock, at cost - 194 shares	(965)	(687)
Accumulated other comprehensive loss, net of tax	(1,675)	(104)
Retained earnings (accumulated deficit)	132,861	76,247
Total Stockholders' Equity	543,934	477,943
Total Liabilities and Stockholders' Equity	1,864,846	1,739,799
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	90,647	14,720	8,878	18,221
Accounts receivable, net	127	21
Inventories	0	0
Deferred income tax assets	251	218
Prepaid expenses and other current assets	8,148	4,942
Total current assets	99,173	19,901
Property and equipment, net	9,905	9,609
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivable	596,369	653,049
Investment in subsidiary	1,536,312	1,429,775
Total Assets	2,241,759	2,112,334
Current liabilities
Current portion of long-term debt	0
Accounts payable	3,063	2,601
Accrued interest payable	0	0
Other accrued liabilities	6,144	12,694
Total current liabilities	9,207	15,295
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Long term liabilities	0
Intercompany payable	1,688,618	1,619,096
Total Liabilities	1,697,825	1,634,391
Stockholders' Equity
Preferred share rights	283	283
Common stock	520	513
Additional paid-in capital	412,910	401,691
Treasury stock, at cost - 194 shares	(965)	(687)
Accumulated other comprehensive loss, net of tax	(1,675)	(104)
Retained earnings (accumulated deficit)	132,861	76,247
Total Stockholders' Equity	543,934	477,943
Total Liabilities and Stockholders' Equity	2,241,759	2,112,334
Prestige Brands, Inc., the issuer
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	14,349	13,875
Inventories	14,660	11,164
Deferred income tax assets	917	855
Prepaid expenses and other current assets	66	93
Total current assets	29,992	25,987
Property and equipment, net	125	34
Goodwill	66,007	66,007
Intangible assets, net	192,995	193,396
Other long-term assets	24,107	24,944
Intercompany receivable	1,919,068	1,911,573
Investment in subsidiary	735,694	638,611
Total Assets	2,967,988	2,860,552
Current liabilities
Current portion of long-term debt	48,290
Accounts payable	11,641	10,600
Accrued interest payable	10,781	13,894
Other accrued liabilities	3,299	1,684
Total current liabilities	74,011	26,178
Long-term debt
Principal amount	985,000	978,000
Less unamortized discount	(3,489)	(7,100)
Long-term debt, net of unamortized discount	981,511	970,900
Deferred income tax liabilities	55,316	55,291
Long term liabilities	0
Intercompany payable	394,359	447,419
Total Liabilities	1,505,197	1,499,788
Stockholders' Equity
Preferred share rights	0	0
Common stock	0	0
Additional paid-in capital	1,337,706	1,280,945
Treasury stock, at cost - 194 shares	0	0
Accumulated other comprehensive loss, net of tax	(1,675)	0
Retained earnings (accumulated deficit)	126,760	79,819
Total Stockholders' Equity	1,462,791	1,360,764
Total Liabilities and Stockholders' Equity	2,967,988	2,860,552
Combined Subsidiary Guarantors
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	47,631	58,345
Inventories	46,020	48,474
Deferred income tax assets	5,668	5,276
Prepaid expenses and other current assets	3,313	3,609
Total current assets	102,632	115,704
Property and equipment, net	229	253
Goodwill	101,540	101,539
Intangible assets, net	1,172,004	1,179,524
Other long-term assets	0	0
Intercompany receivable	588,046	415,587
Investment in subsidiary	8,259	7,067
Total Assets	1,972,710	1,819,674
Current liabilities
Current portion of long-term debt	0
Accounts payable	34,320	37,695
Accrued interest payable	0	0
Other accrued liabilities	10,249	16,107
Total current liabilities	44,569	53,802
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	149,652	138,924
Long term liabilities	0
Intercompany payable	992,745	920,865
Total Liabilities	1,186,966	1,113,591
Stockholders' Equity
Preferred share rights	0	0
Common stock	0	0
Additional paid-in capital	658,799	624,742
Treasury stock, at cost - 194 shares	0	0
Accumulated other comprehensive loss, net of tax	(1,675)	0
Retained earnings (accumulated deficit)	128,620	81,341
Total Stockholders' Equity	785,744	706,083
Total Liabilities and Stockholders' Equity	1,972,710	1,819,674
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	3,706	950	1,553	794
Accounts receivable, net	4,081	812
Inventories	4,994	563
Deferred income tax assets	0	0
Prepaid expenses and other current assets	799	256
Total current assets	13,580	2,581
Property and equipment, net	269	0
Goodwill	22,408	0
Intangible assets, net	30,756	320
Other long-term assets	0	0
Intercompany receivable	9,501	7,316
Investment in subsidiary	0	0
Total Assets	76,514	10,217
Current liabilities
Current portion of long-term debt	0
Accounts payable	2,523	480
Accrued interest payable	0	0
Other accrued liabilities	3,753	913
Total current liabilities	6,276	1,393
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	68	73
Long term liabilities	302
Intercompany payable	37,262	145
Total Liabilities	43,908	1,611
Stockholders' Equity
Preferred share rights	0	0
Common stock	0	0
Additional paid-in capital	23,815	1,111
Treasury stock, at cost - 194 shares	0	0
Accumulated other comprehensive loss, net of tax	(1,675)	(104)
Retained earnings (accumulated deficit)	10,466	7,599
Total Stockholders' Equity	32,606	8,606
Total Liabilities and Stockholders' Equity	76,514	10,217
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories	(876)	0
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(876)	0
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivable	(3,112,984)	(2,987,525)
Investment in subsidiary	(2,280,265)	(2,075,453)
Total Assets	(5,394,125)	(5,062,978)
Current liabilities
Current portion of long-term debt	0
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Long term liabilities	0
Intercompany payable	(3,112,984)	(2,987,525)
Total Liabilities	(3,112,984)	(2,987,525)
Stockholders' Equity
Preferred share rights	0	0
Common stock	0	0
Additional paid-in capital	(2,020,320)	(1,906,798)
Treasury stock, at cost - 194 shares	0	0
Accumulated other comprehensive loss, net of tax	5,025	104
Retained earnings (accumulated deficit)	(265,846)	(168,759)
Total Stockholders' Equity	(2,281,141)	(2,075,453)
Total Liabilities and Stockholders' Equity	$ (5,394,125)	$ (5,062,978)

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Activities
Net income (loss)	$ 56,614	$ 46,156
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	10,209	9,950
Deferred income taxes	10,261	15,979
Amortization of deferred financing costs	6,023	8,220
Stock-based compensation costs	3,763	2,965
Loss on extinguishment of debt	15,012	0
Premium payment on 2010 Senior Notes	(12,768)	0
Lease termination costs	0	975
Amortization of debt discount	3,115	3,892
Gain on sale of assets	(3)	51
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	8,495	(13,518)
Inventories	(2,262)	(3,351)
Prepaid expenses and other current assets	(2,783)	5,801
Accounts payable	(1,285)	14,125
Accrued liabilities	(13,531)	9,631
Net cash provided by operating activities	80,860	100,876
Investing Activities
Purchases of property and equipment	(2,658)	(8,922)
Proceeds from the sale of property and equipment	3	15
Proceeds from the sale of the Phazyme brand	0	21,700
Acquisition of Care Pharmaceuticals, less cash acquired	(55,215)	0
Acquisition of GSK purchase price adjustments	0	(226)
Intercompany activity, net	0	0
Net cash (used in) provided by investing activities	(57,870)	12,567
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	400,000	0
Repayment of 2010 Senior Notes	(201,710)	0
Repayments of long-term debt	(147,500)	(167,500)
Repayments under revolving credit agreement	(45,500)	(8,000)
Borrowings under revolving credit agreement	50,000	48,000
Payment of deferred financing costs	(6,933)	0
Proceeds from exercise of stock options	5,738	5,460
Excess tax benefits from share-based awards	1,725	0
Shares surrendered as payment of tax withholding	(278)	0
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	55,542	(122,040)
Effects of exchange rate changes on cash and cash equivalents	151	13
Increase (decrease) in cash and cash equivalents	78,683	(8,584)
Cash and cash equivalents - beginning of period	15,670	19,015
Cash and cash equivalents - end of period	94,353	10,431
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	56,614	46,156
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,017	818
Deferred income taxes	(33)	143
Amortization of deferred financing costs	0	0
Stock-based compensation costs	3,763	2,965
Loss on extinguishment of debt	0
Premium payment on 2010 Senior Notes	0
Lease termination costs		975
Amortization of debt discount	0	0
Gain on sale of assets	0	30
Equity in income of subsidiaries	(51,347)	(50,008)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(106)	(115)
Inventories	0	0
Prepaid expenses and other current assets	(3,206)	6,446
Accounts payable	462	(3,347)
Accrued liabilities	(6,550)	(1,071)
Net cash provided by operating activities	1,614	2,992
Investing Activities
Purchases of property and equipment	(2,555)	(8,922)
Proceeds from the sale of property and equipment	0	0
Proceeds from the sale of the Phazyme brand		0
Acquisition of Care Pharmaceuticals, less cash acquired	0
Acquisition of GSK purchase price adjustments		0
Intercompany activity, net	0	(226)
Net cash (used in) provided by investing activities	(2,555)	(9,148)
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	0
Repayment of 2010 Senior Notes	0
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0
Proceeds from exercise of stock options	5,738	5,460
Excess tax benefits from share-based awards	1,725
Shares surrendered as payment of tax withholding	(278)
Intercompany activity, net	69,683	(8,647)
Net cash provided by (used in) financing activities	76,868	(3,187)
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	75,927	(9,343)
Cash and cash equivalents - beginning of period	14,720	18,221
Cash and cash equivalents - end of period	90,647	8,878
Prestige Brands, Inc., the issuer
Operating Activities
Net income (loss)	46,941	51,673
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	434	420
Deferred income taxes	(37)	44
Amortization of deferred financing costs	6,023	8,220
Stock-based compensation costs	0	0
Loss on extinguishment of debt	15,012
Premium payment on 2010 Senior Notes	(12,768)
Lease termination costs		0
Amortization of debt discount	3,115	3,892
Gain on sale of assets	0	0
Equity in income of subsidiaries	(41,997)	(49,280)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(474)	285
Inventories	(3,496)	(1,242)
Prepaid expenses and other current assets	27	(369)
Accounts payable	1,041	2,488
Accrued liabilities	(1,498)	529
Net cash provided by operating activities	12,323	16,660
Investing Activities
Purchases of property and equipment	0	0
Proceeds from the sale of property and equipment	0	0
Proceeds from the sale of the Phazyme brand		0
Acquisition of Care Pharmaceuticals, less cash acquired	0
Acquisition of GSK purchase price adjustments		0
Intercompany activity, net	(55,215)	0
Net cash (used in) provided by investing activities	(55,215)	0
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	400,000
Repayment of 2010 Senior Notes	(201,710)
Repayments of long-term debt	(147,500)	(167,500)
Repayments under revolving credit agreement	(45,500)	(8,000)
Borrowings under revolving credit agreement	50,000	48,000
Payment of deferred financing costs	(6,933)
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0
Shares surrendered as payment of tax withholding	0
Intercompany activity, net	(5,465)	110,840
Net cash provided by (used in) financing activities	42,892	(16,660)
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	47,279	47,848
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	7,624	8,667
Deferred income taxes	10,336	15,796
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Premium payment on 2010 Senior Notes	0
Lease termination costs		0
Amortization of debt discount	0	0
Gain on sale of assets	(3)	21
Equity in income of subsidiaries	(2,867)	(1,306)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	10,714	(13,474)
Inventories	2,454	(2,104)
Prepaid expenses and other current assets	296	(627)
Accounts payable	(3,375)	14,095
Accrued liabilities	(5,858)	9,830
Net cash provided by operating activities	66,600	78,746
Investing Activities
Purchases of property and equipment	0	0
Proceeds from the sale of property and equipment	3	15
Proceeds from the sale of the Phazyme brand		21,700
Acquisition of Care Pharmaceuticals, less cash acquired	0
Acquisition of GSK purchase price adjustments		(226)
Intercompany activity, net	0	226
Net cash (used in) provided by investing activities	3	21,715
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	0
Repayment of 2010 Senior Notes	0
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0
Shares surrendered as payment of tax withholding	0
Intercompany activity, net	(66,603)	(100,461)
Net cash provided by (used in) financing activities	(66,603)	(100,461)
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)	2,867	1,073
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	134	45
Deferred income taxes	(5)	(4)
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Premium payment on 2010 Senior Notes	0
Lease termination costs		0
Amortization of debt discount	0	0
Gain on sale of assets	0	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(1,639)	(214)
Inventories	(2,096)	(5)
Prepaid expenses and other current assets	100	351
Accounts payable	587	889
Accrued liabilities	375	343
Net cash provided by operating activities	323	2,478
Investing Activities
Purchases of property and equipment	(103)	0
Proceeds from the sale of property and equipment	0	0
Proceeds from the sale of the Phazyme brand		0
Acquisition of Care Pharmaceuticals, less cash acquired	(55,215)
Acquisition of GSK purchase price adjustments		0
Intercompany activity, net	55,215	0
Net cash (used in) provided by investing activities	(103)	0
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	0
Repayment of 2010 Senior Notes	0
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0
Shares surrendered as payment of tax withholding	0
Intercompany activity, net	2,385	(1,732)
Net cash provided by (used in) financing activities	2,385	(1,732)
Effects of exchange rate changes on cash and cash equivalents	151	13
Increase (decrease) in cash and cash equivalents	2,756	759
Cash and cash equivalents - beginning of period	950	794
Cash and cash equivalents - end of period	3,706	1,553
Eliminations
Operating Activities
Net income (loss)	(97,087)	(100,594)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	0	0
Deferred income taxes	0	0
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt	0
Premium payment on 2010 Senior Notes	0
Lease termination costs		0
Amortization of debt discount	0	0
Gain on sale of assets	0	0
Equity in income of subsidiaries	96,211	100,594
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	0
Inventories	876	0
Prepaid expenses and other current assets	0	0
Accounts payable	0	0
Accrued liabilities	0	0
Net cash provided by operating activities	0	0
Investing Activities
Purchases of property and equipment	0	0
Proceeds from the sale of property and equipment	0	0
Proceeds from the sale of the Phazyme brand		0
Acquisition of Care Pharmaceuticals, less cash acquired	0
Acquisition of GSK purchase price adjustments		0
Intercompany activity, net	0	0
Net cash (used in) provided by investing activities	0	0
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	0
Repayment of 2010 Senior Notes	0
Repayments of long-term debt	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0
Proceeds from exercise of stock options	0	0
Excess tax benefits from share-based awards	0
Shares surrendered as payment of tax withholding	0
Intercompany activity, net	0	0
Net cash provided by (used in) financing activities	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	$ 0	$ 0

Subsequent Events (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended	3 Months Ended	0 Months Ended
Subsequent Events (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 17, 2013 2010 Senior Notes Senior Notes	Dec. 31, 2013 2010 Senior Notes Senior Notes	Jan. 16, 2014 2010 Senior Notes Senior Notes Subsequent Event	Jan. 16, 2014 Sales Supplier Concentration Risk Subsequent Event supplier
Subsequent Event [Line Items]
Premium percentage					6.33%
Repayments of debt			$ 201,710,000	$ 0	$ (201,700,000)		$ 48,300,000
Loss on extinguishment of debt	15,012,000	0	15,012,000	0		15,000,000
Additional loss on extinguishment of debt							3,300,000
Tendered debt							$ 48,300,000
Number of suppliers contributing to production stoppage								1
Production stoppage percentage								8.00%